

1 ***Salmonella* succinate utilisation is inhibited by multiple**
2 **regulatory systems**

3

4 Nicolas Wenner^{1*}, Xiaojun Zhu¹, Will P. M. Rowe¹, Kristian Händler² and Jay
5 C. D. Hinton¹

6

7 ¹Clinical Infection, Microbiology & Immunology, Institute of Infection, Veterinary &
8 Ecological Sciences, University of Liverpool, Liverpool, United Kingdom

9

10 ²Department of Microbiology, School of Genetics and Microbiology, Moyne Institute of
11 Preventive Medicine, Trinity College Dublin, Dublin, Ireland

12

13 *To whom correspondence should be addressed. Email: nicolas.wenner@gmail.com

14

15 Current address: Nicolas Wenner, Biozentrum, University of Basel, CH-4056 Basel,
16 Switzerland; Kristian Händler, Institute of Human Genetics, University Hospital of
17 Schleswig-Holstein, University of Lübeck, Lübeck, Germany.

18

19 Running title: Genetic dissection of inhibition of succinate utilisation in *Salmonella*

20

21 **Abstract**

22 Succinate is a potent immune signalling molecule that is present in the mammalian gut
23 and within macrophages. Both of these niches are colonised by the pathogenic bacterium
24 *Salmonella enterica* serovar Typhimurium during infection. Succinate is a C₄-dicarboxylate
25 that can serve as a source of carbon for bacteria. When succinate is provided as the sole
26 carbon source for *in vitro* cultivation, *Salmonella* and other enteric bacteria exhibit a slow
27 growth rate and a long lag phase. This growth inhibition phenomenon was known to
28 involve the sigma factor RpoS, but the genetic basis of the repression of bacterial
29 succinate utilisation was poorly understood. Here, we used an experimental evolution
30 approach to isolate fast-growing mutants during growth of *S. Typhimurium* on succinate
31 containing minimal medium.

32
33 Our approach reveals novel RpoS-independent systems that inhibit succinate utilisation.
34 The CspC RNA binding protein restricts succinate utilisation, an inhibition that is
35 antagonised by high levels of the small regulatory RNA (sRNA) OxyS. We discovered that
36 the Fe-S cluster regulatory protein IscR inhibits succinate utilisation by repressing the C₄-
37 dicarboxylate transporter DctA.

38
39 The RNA chaperone Hfq, the exoribonuclease PNPase and their cognate sRNAs function
40 together to repress succinate utilisation *via* RpoS induction. Furthermore, the ribose
41 operon repressor RbsR is required for the complete RpoS-driven repression of succinate
42 utilisation, suggesting a novel mechanism of RpoS regulation.

43
44 Our discoveries shed light on redundant regulatory systems that tightly regulate the
45 utilisation of succinate. We propose that the control of central carbon metabolism by
46 multiple regulatory systems in *Salmonella* governs the infection niche-specific utilisation of
47 succinate.

48

49 Introduction

50

51 Metabolic versatility is a key property that allows pathogenic enteric bacteria to thrive both
52 during infection of mammals and in the wider environment [1]. C₄-dicarboxylates are an
53 important part of the bacterial catabolic repertoire, which can be utilised as a sole carbon
54 and energy source (C-source) [2]. In the mammalian gut, the C₄-dicarboxylate succinate is
55 an abundant C-source that is provided by the microbiota in response to the presence of
56 dietary fibre [3]. *Salmonella enterica* serovar Typhimurium (*S. Typhimurium*) is one of the
57 best understood enteropathogenic bacterium [4] which efficiently catabolises succinate
58 during intestinal colonisation to enhance the growth [5].

59

60 As well as colonising the mammalian gut, *Salmonella* can also cross the intestinal
61 epithelial barrier and invade several types of tissues [6]. An important element of the
62 pathogenic lifestyle of *S. Typhimurium* involves the hijacking of macrophages, and the
63 intracellular proliferation of the bacteria within *Salmonella*-containing vacuoles (SCVs) [7].
64 Recently, it has been discovered that macrophages undergo metabolic reprogramming
65 during bacterial infection, leading to the build-up of tricarboxylic acid (TCA) cycle
66 intermediates, including succinate [8]. This C₄-dicarboxylate acts as an important
67 proinflammatory molecule that is also involved in hypoxic and metabolic signalling [9,10].
68 Following infection by *S. Typhimurium*, high levels of succinate accumulate within
69 macrophages [11]. However, *Salmonella* does not use this succinate to fuel growth as
70 glucose and the glycolytic intermediate 3-phosphoglycerate are the key intra-macrophage
71 C-sources [11–13]

72

73 The inactivation of key succinate catabolic genes does not reduce the ability of *S.*
74 *Typhimurium* to replicate in murine macrophages, but stimulates intracellular proliferation
75 [14]. Although succinate is not utilised as a C-source by *Salmonella* in the SCV, the
76 metabolite does act as a crucial signal molecule for the induction of the *Salmonella*
77 Pathogenicity Island 2 (SPI2) system [13], which is required for macrophage infection [15].

78

79 During *in vitro* cultivation, *S. Typhimurium* exhibits a particularly extended lag phase in
80 minimal axenic media containing succinate as sole C-source; in contrast, succinate
81 supports the rapid growth of other enteric bacteria such as *Escherichia coli* [16], *via* the
82 succinate dehydrogenase (SDH) multi-enzyme complex that oxidises succinate into

83 fumarate [17]. Subsequent, bacterial replication with succinate involves the generation of
84 all cellular components *via* gluconeogenesis [2,18].

85 The stress response sigma factor σ^{38} (RpoS) is a global transcriptional regulator that
86 modulates diverse facets of *Salmonella* biology including stress-resistance, immobilised
87 growth, virulence and nutrient assimilation [19–22]. RpoS inhibits *in vitro* growth upon
88 succinate by repressing transcription of the *sdhCDAB* operon (*sdh*) and other TCA cycle
89 genes [23–25].

90

91 Because *Salmonella* utilises succinate for colonisation of the inflamed gut [5] but not for
92 intra-macrophage proliferation [13,14], we hypothesised that *Salmonella* had evolved
93 multiple genetic regulatory mechanisms to tightly control the niche-dependent utilisation of
94 this infection-relevant molecule.

95

96 Here, we devised an *in vitro* experimental strategy to search for novel regulatory
97 mechanisms involved in the modulation of succinate utilisation. Our genetic dissection
98 identified two novel RpoS-independent regulatory mechanisms that repress succinate
99 utilisation *via* the CspC and IscR regulatory proteins. In addition, the modulation of RpoS
100 activity by Hfq, PNPase and RbsR also impacted upon succinate utilisation. We propose
101 that this multi-factorial system ensures that succinate is only catabolised at the right place
102 and at the right time during infection to permit effective niche adaptation.

103

104 **Results and Discussion**

105

106 **Growth inhibition and evolution in succinate minimal medium**

107

108 Enteric bacteria possess the catabolic enzymes and efficient uptake systems required to
109 grow with C₄-dicarboxylates as sole C-source [2,26]. However, some environmental and
110 clinical isolates of *Escherichia coli* and *Salmonella* have surprisingly slow growth rates in
111 succinate-containing minimal media [27–29]. To investigate this phenomenon in
112 pathogenic and non-pathogenic enteric bacteria, we assessed the growth of four bacterial
113 species on agar plates containing succinate as a sole C-source (M9+Succ). We studied
114 growth for up to 96 hours, and used a variety of laboratory strains with an emphasis on
115 *Salmonella* (Fig 1).

116

117 For *S. enterica* serovars Typhimurium and Enteritidis, we tested the growth of the well-
118 characterised *S. Typhimurium* strains LT2, 4/74 and 14028 and of the *S. Enteritidis* strain
119 P125109. In addition, we assessed the growth of multidrug resistant *S. Typhimurium*
120 ST313 strain D23580 and *S. Enteritidis* strain D7795, two representative strains that cause
121 invasive non-typhoidal *Salmonella* disease in Africa [30–32]. We included the reptile-
122 associated *Salmonella* serovars Soahanina, Hadar, Newport and Infantis which belong to
123 the two metabolically-distinct clades A and B of *S. enterica* [33,34]. We and others have
124 previously generated genome sequences of most of the *Salmonella* strains that were used
125 [32,33,35]. We also tested a multidrug resistant strain of *Klebsiella pneumoniae* (strain
126 KP52.145) [36], a *Citrobacter rodentium* strain (ATCC51459) [37] and the classic
127 laboratory strain *E. coli* K-12 strain MG1655.

128

129 After 24 hours of incubation at 37°C, the only strains that displayed substantial growth with
130 succinate as a C-source were *S. Typhimurium* LT2, *E. coli* MG1655 and *C. rodentium*
131 ATCC51459. Following 2-3 days of incubation, large colonies were observed within the
132 bacterial lawns of the *K. pneumoniae* strain and the other *Salmonella* isolates. The only
133 *Salmonella* serovar that displayed substantial growth after 2 days was *S. Newport*,
134 showing that growth on succinate is a serovar-dependent phenotype.

135

136 Previous experiments in liquid minimal medium containing succinate as sole C-source
137 showed that *S. Typhimurium* exhibited a particularly long lag phase [16,23]. This extended
138 lag time could reflect a particularly slow metabolic remodelling, preparing *Salmonella* for

139 the exponential phase in the presence of succinate. Alternatively, robust inhibition of
140 succinate assimilation might be occurring under these conditions, preventing growth until
141 spontaneous fast-growing mutants (hereafter referred as Succ⁺ mutants) have emerged.

142

143 To test these hypotheses, we assessed the growth of the well-characterised *S.*
144 Typhimurium strain 4/74 (henceforth referred to as 4/74 or *Salmonella*) in liquid M9+Succ
145 media inoculated with a stationary phase culture made in rich medium (LB). The four
146 independent 4/74 cultures (cultures I-IV) exhibited the reported 30-35 hour lag time at
147 37°C [16,23] (Fig 2A). We collected the *Salmonella* that eventually reached stationary
148 phase and cultured the bacteria in LB for two passages before re-inoculation in M9+Succ.
149 For all the succinate-evolved cultures, the lag time in M9+Succ was reduced to 4-5 hours,
150 and stationary phase was reached after approximately 14 hours (Fig 2B).

151

152 To investigate heritability of the succinate growth phenotype, the initial M9+Succ cultures
153 (Fig 2A) were spread on LB agar plates at different stages of growth, and isolated colonies
154 were tested on M9+Succ plates. Of 60 colonies obtained from lag phase, none grew faster
155 than the wild type (Fig 2C). However, fast growing Succ⁺ mutants harvested from early
156 exponential, mid-exponential and early stationary phase culture were detected at a
157 frequency of 20 %, 78 % and 90 %, respectively (Fig 2C). When ~10⁷ Colony Forming
158 Units (CFU) of 4/74 wild-type (WT) were spread on M9+Succ plates, between 100 and
159 1000 Succ⁺ colonies grew in the bacterial lawn after 3 days of incubation (Fig 2D).

160

161 Collectively, these results indicated that, in our experimental setup, *Salmonella* growth
162 upon succinate was consistently inhibited. The eventual initiation of exponential phase did
163 not result from an orchestrated metabolic switch, but reflected the emergence of
164 spontaneous mutants that efficiently utilised succinate, and proliferated to outcompete the
165 WT bacteria. This Succ⁺ phenotype remained stable after two passages on LB medium,
166 indicating that the trait was not a phase-variable phenomenon caused by epigenetic
167 mechanisms, as has been observed for other reversible phenotypes in *Salmonella* [38,39].
168 Moreover, our data suggest that other pathogenic bacteria, such as *Klebsiella* also
169 suppress succinate assimilation (Fig 1).

170

171 Here, we define “succinate utilisation” as the ability of *Salmonella* to grow with succinate
172 as a sole carbon and energy source. We selected *S. Typhimurium* strain 4/74 for further
173 study of the suppression of succinate utilisation because it is the parent of strain SL1344,

174 which has been used for a plethora of regulatory and infection studies in the past [40]. We
175 aimed to identify novel genetic determinants involved in the control of the uptake and
176 catabolism of this infection-relevant C-source.

177

178 **Identification of novel mutations that abolish inhibition of succinate utilisation**

179

180 To identify mutations that ablate the inhibition of succinate utilisation, we used three
181 complementary unbiased approaches. We first screened a collection of published *S.*
182 *Typhimurium* 4/74 mutants [41] that lacked key regulatory proteins (Fig S1A), and focused
183 on mutations that both promoted growth on succinate agar plates and in liquid medium
184 with aeration. This screen revealed that mutants lacking the RNA chaperone Hfq (Δhfq)
185 and the polynucleotide phosphorylase (PNPase, mutant Δpnp) had a Succ⁺ phenotype.
186 Complementation with low-copy plasmids carrying *hfq*⁺ or *pnp*⁺, restored the Succ⁻ WT
187 phenotype in the corresponding mutant (Fig S3C & D).

188

189 To explore metabolic suppression in more depth, we used global Tn5 transposon
190 mutagenesis to generate insertions that promoted growth on succinate (Methods). RpoS
191 has a key role in the inhibition of succinate utilisation [27–29] and *rpoS* inactivation did
192 cause the drastic shortening of the lag time of 4/74 in M9+Succ, similarly to the succinate
193 evolved cultures (Fig 2B, Fig S1B, Fig S3B). Therefore, we developed a strategy to avoid
194 the selection of Succ⁺ *rpoS* mutants by constructing a strain that carried two chromosomal
195 copies of *rpoS* (4/74 *rpoS*^{2X}; Fig S1B-C). Following Tn5 mutagenesis of the *rpoS*^{2X} strain,
196 individual Succ⁺ Tn5 mutants were isolated. The Tn5 insertions were P22-transduced into
197 4/74 WT and the Succ⁺ phenotype of the transductants was confirmed (Table 1).

198

199 In parallel, we isolated spontaneous Succ⁺ mutants from either M9+Succ agar plates (Fig
200 2D) or from liquid cultures (Methods). We first verified the RpoS positive (*rpoS*⁺) status of
201 each spontaneous Succ⁺ mutant (Methods), and then used whole genome-sequencing to
202 identify relevant nucleotide changes, which were associated with seven genes (Table 1).

203

204 These complementary genetic screens identified Succ⁺ mutants that carried Tn5 insertions
205 in *iraP*, *cspC*, *rbsR* and *fliD* or in the 5' untranslated region (5'-UTR) of the *yobJ-cspC*
206 operon (Table 1). In addition, a nonsense spontaneous mutation in *iscR* (*yfhP*) and a
207 spontaneous in-frame insertion of 4 codons in *rbsR* were identified in spontaneous Succ⁺
208 mutants (Table 1). To independently confirm the function of these genes, λ *red*

209 recombination was used to generate $\Delta iraP$, $\Delta cspC$, $\Delta rbsR$ and $\Delta iscR$ deletion mutants.
210 Each of the four mutants had the Succ⁺ phenotype (Fig 3). We confirmed that the
211 corresponding WT proteins could inhibit succinate utilisation by plasmid-borne
212 complementation experiments (Fig S3 E-H).

213

214 We found that inactivation of *fliD* alone did not cause a Succ⁺ phenotype (Fig S2A). The
215 *fliD* gene is co-transcribed with the downstream *fliS* and *fliT* genes [42]. Tn5 insertions
216 may have polar effects on the expression of surrounding genes [43], raising the possibility
217 that the *fliD*::Tn5 insertion modulated expression of *fliS* or *fliT*. Our genetic dissection of
218 the *fliDST* operon revealed that inactivation of either *fliS* or *fliT* caused the Succ⁺
219 phenotype, suggesting that the two genes contribute to the inhibition of succinate
220 utilisation (Fig S2A). The Succ⁺ phenotype of the $\Delta fliST$ mutant was confirmed, and
221 complementation of the double mutation restored the WT Succ⁻ phenotype (Fig S3I).

222

223 It is known that the IraP anti-adaptor controls succinate metabolism by modulating RpoS
224 stability at the protein level [16]. The fact that we identified an *iraP*::Tn5 mutant was an
225 effective validation of the use of the *rpoS*^{2X} genetic background for the transposon
226 mutagenesis.

227

228 During the complementation experiments, we observed that the presence of
229 chloramphenicol (Cm) mildly stimulated the growth of the WT strain (Fig S3J), an
230 observation that will be investigated below.

231

232 Certain spontaneous mutations that stimulated growth with succinate did not reflect a
233 typical loss-of-function scenario. For example, one of the spontaneous Succ⁺ mutants had
234 an additional CTA codon resulting in an extra leucine between residues 239 and 240 of
235 the transcriptional regulator OxyR (mutant *oxyR*^{mut1}) (Table 1). We also identified two Succ⁺
236 mutants with a single nucleotide polymorphism (SNP) located in the 5'-UTR of *dctA*
237 (mutants *dctA*^{mut1} and *dctA*^{mut2}, Table 1), that encodes for the aerobic succinate
238 transporter DctA [44]. Finally, two Succ⁺ mutants carried a SNP in the anti-Shine-Dalgarno
239 sequence of the *rrsA* and *rrsH* genes that encode two 16S ribosomal RNAs; mutants
240 *rrsA*^{mut} and *rrsH*^{mut} (Table 1). The function of the mutations associated with genes *oxyR*,
241 *dctA*, *rrsA* and *rrsH* was confirmed by scarless genomic editing to generate exactly the
242 same nucleotide changes in the WT background (Methods). All these reconstructed
243 mutations caused the Succ⁺ phenotype (Fig 3).

244

245 In summary, we identified novel mutations that promote *Salmonella* growth upon
246 succinate. These included mutations that involved the transcriptional regulators (RbsR,
247 IscR, OxyR), RNA binding proteins (PNPase, Hfq and CspC), flagellar protein chaperones
248 (FliS and FliT) and in ribosomal RNAs (RrsA and RrsH) (Fig 3). The eleven novel Succ⁺
249 mutations also promoted *Salmonella* growth upon fumarate or malate, suggesting that the
250 regulatory systems play a general role in the de-inhibition of C₄-dicarboxylate utilisation
251 (Supplementary Fig S1D).

252

253 **Hfq, PNPase and their cognate sRNAs maintain the inhibition of succinate** 254 **utilisation**

255

256 Our discovery that the inactivation of the RNA binding proteins Hfq and PNPase promoted
257 *Salmonella* growth upon succinate (Fig 3) led us to investigate the phenotype in more
258 detail. In liquid culture, the Δhfq and Δpnp mutants displayed a lag time of ~5 hours and
259 ~15 hours, respectively (Fig 4A), prompting experiments to investigate the role of small
260 regulatory RNAs (sRNAs) in the inhibition of succinate utilisation.

261

262 The RNA chaperone Hfq and its associated sRNAs are key post-transcriptional regulatory
263 determinants [45,46]. In *E. coli*, the sRNAs RybB, RyhB (RyhB-1 in *Salmonella*) and
264 Spot42 (Spf) base-pair with the *sdhC* 5'-UTR to repress *sdhC* translation in an Hfq-
265 dependent manner. In addition, RybB and RyhB reduce the stability of the *sdh* mRNA
266 [47,48]. We reasoned that the observed Succ⁺ phenotype of the Hfq null mutant could
267 reflect de-repression of the *sdh* mRNA at the translational level.

268

269 In *E. coli*, the iron-dependent sRNA RyhB represses growth with succinate under iron-
270 limited conditions [49]. Because exogenous iron was not added to our M9 media, we
271 investigated whether the inhibition of *Salmonella* growth with succinate was the
272 consequence of the *sdh* repression by RyhB-1 or RyhB-2, the RyhB-1 paralog in
273 *Salmonella* [50]. Neither iron (FeCl₃) supplementation (up to 100 μ M) or the double
274 inactivation of RyhB-1 and RyhB-2 (strain $\Delta ryhB-1/2$) generated a Succ⁺ phenotype
275 (Supplementary Fig S4). Similarly, the simultaneous inactivation of four sRNAs (RybB,
276 Spf, RyhB-1 and RyhB-2) did not affect growth on M9+Succ (Fig 4B).

277

278 Hfq and sRNAs are crucial for the stimulation of *rpoS* translation. The long 5'-UTR of *rpoS*
279 mRNA forms a self-inhibitory hairpin secondary structure, that blocks the ribosome access

280 to the ribosome binding site, repressing *rpoS* mRNA translational initiation [51]. In *E. coli*,
281 base-pairing of the sRNAs ArcZ, DsrA and RprA with the *rpoS* 5'-UTR, relieves this self-
282 repression in an Hfq-dependent manner to stimulate *rpoS* translation [52]. In addition,
283 binding of ArcZ, DsrA and RprA to the *rpoS* 5'-UTR prevents the premature Rho-
284 dependent transcription termination of the *rpoS* mRNA [53]. As RpoS plays a pivotal role in
285 the control of succinate utilisation, we assessed the growth of the triple $\Delta arcZ rprA dsrA$
286 mutant in M9+Succ. In comparison with the WT strain, no obvious differences were
287 observed (Fig 4B). However, the successive deletion of sRNAs *arcZ*, *dsrA* and *rprA* in the
288 $\Delta rybB spf ryhB-1/2$ genetic background did promote growth on succinate, and gradually
289 reduced the duration of lag time (Fig 4C).

290

291 Inactivation of *pnp* is known to restore growth of a RyhB-overexpressing *E. coli* strain on
292 succinate by reducing the stability of several sRNAs, including RyhB [54]. The same study
293 demonstrated that the translational activation of *rpoS* by RprA and DsrA was attenuated in
294 the Δpnp background. To test whether PNPase inactivation boosted succinate utilisation
295 through RpoS attenuation, we assessed the growth of a Δpnp mutant that overexpressed
296 *rpoS*. The plasmid-borne overexpression of *rpoS* in this strain totally suppressed the Succ⁺
297 phenotype (Fig 4D), consistent with the stimulation of RpoS expression by PNPase.

298

299 Taken together, these results indicate that the fast growth of the Δhfq and Δpnp strains
300 reflected both the dysregulation of the sRNA-mediated repression of *sdh* and the
301 activation of *rpoS* translation. However, none of the sRNA mutants tested displayed the
302 same fast-growing pattern of the Δhfq mutant, suggesting that other sRNAs may be
303 involved in the inhibition of succinate utilisation.

304 **The OxyS sRNA stimulates growth upon succinate by repressing expression of** 305 **CspC**

306

307 The spontaneous Succ⁺ mutants included an *oxyR* variant (*oxyR^{mut}*) that encoded an extra
308 leucine residue in the C-terminus domain of the OxyR transcriptional regulator (Table 1,
309 Fig 5A). OxyR senses oxidative stress and is activated by disulfide bond formation in the
310 presence of reactive oxygen species [55,56]. In *E. coli*, the OxyR regulon includes about
311 40 genes, mainly associated with oxidative stress resistance [57,58]. In addition, the
312 oxidized form of OxyR triggers the transcription of OxyS, an Hfq-binding sRNA [59–61].
313 Previous studies reported the isolation of constitutively-active OxyR variants that carried
314 mutations in the same region as the extra leucine residue of the *oxyR^{mut}* variant [62–64].

315

316 Consequently, we investigated whether the *oxyR^{mut}* allele drove constitutive transcription
317 of the OxyS sRNA. Northern blot analysis revealed that OxyS was strongly expressed both
318 in the absence and in the presence of hydrogen peroxide in the *oxyR^{mut}* strain, indicating
319 that the OxyR^{mut} protein is constitutively active (Fig 5B). We then determined whether
320 OxyS constitutive expression was responsible for the Succ⁺ phenotype of the *oxyR^{mut}*
321 mutant. The deletion of *oxyS* in the *oxyR^{mut}* strain (*oxyR^{mut} ΔoxyS*) totally abolished the
322 Succ⁺ phenotype (Fig 5C). A complementation experiment was carried out by re-
323 introducing a single copy of *oxyS* and its native promoter (*oxyS^{chr+}*, Fig S5) into the
324 chromosome of the *oxyR^{mut} ΔoxyS* strain (Methods). This chromosomal complementation
325 restored the fast growth of the *oxyR^{mut} ΔoxyS* mutant in M9+Succ (Fig 5C). Furthermore,
326 the plasmid-borne expression of OxyS boosted the growth of 4/74 WT in M9+Succ,
327 confirming that high level expression of the OxyS sRNA stimulated growth with succinate
328 (Fig 5D). The same plasmid did not stimulate the growth of the *ΔoxyR* strain indicating that
329 a functional OxyR is required for growth in M9+Succ (Fig 5D). We previously showed that
330 Hfq inactivation boosted succinate utilisation (Fig 4A), but in the *oxyR^{mut}* genetic
331 background the same Hfq inactivation dramatically reduced growth and extended the
332 duration of lag time in M9+Succ (Fig 5 E). Collectively, our findings show that the OxyS
333 sRNA orchestrates the de-inhibition of succinate utilisation in an Hfq-dependent manner.

334

335 In *E. coli*, OxyS acts as an indirect repressor of RpoS expression, probably *via* the titration
336 of Hfq [60]. OxyS also represses the expression of the *yobF-cspC* operon, probably by
337 base-pairing near the SD motif of the *yobF* 5'-UTR [65,66]. Because RpoS, Hfq and CspC
338 repress succinate utilisation (Fig 3), we tested the effects of the plasmid-borne
339 overexpression of *rpoS⁺*, *hfq⁺* or *cspC⁺* on the growth of the *oxyR^{mut}* strain. The
340 overexpression of Hfq and RpoS slightly increased the lag time of *OxyR^{mut}* strain, while the
341 plasmid-borne expression of CspC totally abolished the Succ⁺ phenotype in this genetic
342 background (Fig 6A).

343

344 To confirm that the OxyS-driven repression of the *yobF-cspC* was conserved in
345 *Salmonella* we used a plasmid-borne *yobF::sfGFP* translational reporter (Fig 6B). In
346 comparison with the WT, the *yobF::sfGFP* activity was significantly lower in the *oxyR^{mut}*
347 strain (~2-fold repression), confirming that OxyS represses the expression of the *yobF-*
348 *cspC* operon in *Salmonella* (Fig 6C). Bioinformatic analyses identified the putative
349 secondary structures and the potential base-pairing interaction between OxyS and the

350 *yobF* 5'-UTR (Fig 6D), which was predicted to be an 11 nucleotide-long kissing complex
351 between OxyS and the *yobF* 5'-UTR, consistent with the proposed interaction in *E. coli*
352 [66] (Fig 6D).

353

354 To assess the role of the kissing complex experimentally, we generated a mutated version
355 of OxyS with a CC→GG mutation in the loop of the first RNA hairpin (allele *oxyS^{GG}*, Fig
356 6D). This mutation was introduced into the chromosome of the *oxyR^{mut}* strain (strain
357 *oxyR^{mut} oxyS^{GG}*) and the *oxyS^{GG}* gene was cloned into the pP_L expression vector [67]. The
358 empty pP_L vector, the pP_L-*oxyS* or the pP_L-*OxyS^{GG}* plasmids were transferred into the
359 Δ *oxyS* mutant carrying the *yobF::s::gfp* fusion and the GFP signal was measured. In
360 comparison with the empty pP_L vector, in the presence of the pP_L-*oxyS* (*oxyS⁺⁺*) reduced
361 the GFP fluorescence intensity by ~3-fold, but only by ~1.5-fold in the presence of the pP_L-
362 *oxyS^{GG}* (*oxyS^{GG}++*) (Fig 6E). Consistent with the attenuated repression of *yobF* in the
363 presence of *OxyS^{GG}*, the *oxyR^{mut} oxyS^{GG}* strain had a longer lag time than the *oxyR^{mut}*
364 mutant, confirming that the mutated region of OxyS is involved in the de-inhibition of
365 succinate utilisation (Fig 6F).

366

367 In *E. coli*, CspC stabilises *rpoS* mRNA and increases the cellular level of RpoS [68,69]. To
368 investigate whether the Succ⁺ phenotype of the CspC null mutant was caused by changes
369 in RpoS expression, we tested the effect of RpoS overexpression in the Δ *cspC* mutant (Fig
370 6G). The plasmid-encoded overexpression of RpoS only marginally extended lag time in
371 the Δ *cspC* mutant, indicating that repression of succinate utilisation by CspC is RpoS-
372 independent. A recent study corroborated this observation, as the CspC-mediated
373 activation of RpoS was not observed in *Salmonella* [70].

374

375 Collectively, our results indicate that the OxyS sRNA is a key determinant in the de-
376 inhibition of succinate utilisation by *Salmonella*. Despite the fact that OxyS can regulate
377 RpoS expression levels, we propose that OxyS stimulates the Succ⁺ phenotype by
378 repressing the expression of CspC *via* base-pairing in the vicinity of the *yobF* SD motif.

379

380 CspC is an RNA binding protein, belonging to the cold shock protein family [71]. CspC and
381 its paralog CspE often have redundant functions, being involved in biofilm formation,
382 motility, stress resistance and virulence modulation in *S. Typhimurium* [68,70]. It remains
383 unclear how the OxyS-driven inhibition of CspC expression impacts upon the catabolism of
384 succinate. One possibility is that CspC directly represses succinate catabolic genes. In line

385 with this hypothesis, a transcriptomic study in *S. Typhimurium*, revealed that the *sdhC*,
386 *sdhD* and *sdhA* genes are moderately up-regulated in a $\Delta cspEC$ mutant [70].
387

388 **The iron-sulphur cluster regulator IscR inhibits growth upon succinate by**
389 **repressing DctA expression**

390

391 In *E. coli*, the C₄-dicarboxylate transporter DctA mediates succinate uptake under aerobic
392 conditions [44]. DctA is also a C₄-dicarboxylate co-sensor and modulates the expression of
393 several genes, including *dctA* itself, in concert with the two-component system DcuR/S
394 [72]. The transcription of *dctA* is controlled by catabolic repression and putative CRP
395 binding sites, conserved in *Salmonella*, have been identified in the *dctA* promoter region
396 [73,74] (Fig 7A).

397

398 To determine whether DctA was required for *Salmonella* growth under our experimental
399 conditions, we constructed a chromosomal inducible *dctA* construct, by replacing the *dctA*
400 promoter with *tetR* (encoding the TetR repressor) and the *tetA* promoter (strain *tetR-P_{tetA}-*
401 *dctA*, Fig 7B). In the absence of anhydrotetracycline (AHT) inducer, the *tetR-P_{tetA}-dctA*
402 strain did not grow at all in M9+Succ. However, upon addition of AHT, the *tetR-P_{tetA}-dctA*
403 strain displayed a fast growth phenotype that was not observed with the WT (Fig 7B). We
404 conclude that *Salmonella* requires the DctA transporter to grow on succinate and that *dctA*
405 expression is likely to be repressed in the WT, as previously hypothesised by Hersch and
406 co-workers [16].

407

408 The two spontaneous Succ⁺ mutants *dctA^{mut1}* and *dctA^{mut2}* (Table1) carry SNPs in the 5'-
409 UTR of *dctA* (Fig 7A), and both promoted growth with succinate (Fig 7B). We reasoned
410 that the Succ⁺ mutations could de-repress *dctA* expression, which we examined with a
411 chromosomal *dctA::sgfp* transcriptional/translational reporter fusion in the Succ⁺ mutant
412 backgrounds (Methods and Fig 7C). To allow homogenous growth for all the strains
413 (including the Succ⁻ 4/74 WT), bacteria were grown in M9 supplemented with both glycerol
414 (40 mM) as the main C-source and the addition of 10 mM succinate, to stimulate
415 expression of succinate-induced genes [75]. The GFP fluorescence intensity of single
416 bacteria was measured for each strain by flow cytometry. In comparison with low levels of
417 GFP fluorescence seen in the 4/74 WT background, higher GFP levels were only
418 observed in the presence of the *dctA^{mut1}*, *dctA^{mut2}* and Δ *iscR* mutations (Supplementary
419 Fig S6 A-N). The regulation was confirmed by fluorescence microscopy (Fig 7C) and flow
420 cytometry, using biological triplicates (Fig 7D).

421

422 A recent report proposed that RpoS indirectly represses *dctA* in *Salmonella* [16], but such
423 an increase of the *dctA::sfGFP* fusion activity was not observed in the $\Delta rpoS$ strain under our
424 experimental conditions (Fig 7D, Supplementary Fig S6 P). Of note, the *dctA::sfGFP*-tagged
425 $\Delta rpoS$, *dctA^{mut1}*, *dctA^{mut2}* and $\Delta iscR$ mutants grew much faster in M9+Succ than the
426 isogenic WT strain (Supplementary Fig S6O), with the same growth rate we observed
427 previously with the corresponding untagged mutants (Fig 7B&E and Fig S1B). This
428 indicated that the C-terminal addition of sfGFP did not impede the function of DctA as a
429 succinate transporter or co-sensor.

430

431 The up-regulation of *dctA* in the *Salmonella* IscR null mutant was consistent with the IscR-
432 driven repression of *dctA* proposed in *E. coli* [76]. In most Gram-negative bacteria, the
433 dual regulator IscR controls the transcription of the iron-sulphur (Fe-S) cluster biosynthesis
434 operon *iscRSUA* and the sulphur mobilization genes *sufABCDSE* [77,78]. The apoprotein
435 form of IscR (apo-IscR) is matured by the Isc system into its [Fe₂-S₂]-containing holo-form.
436 The resulting holo-IscR represses the expression of several genes including the *isc*
437 operon. Under iron-limitation and in the presence of reactive oxygen species, the IscR
438 apo-form predominates and stimulates the expression of the *suf* operon, in concert with
439 OxyR [77,79]. IscR binds to two classes of DNA motifs: the Type 1 motifs are only bound
440 by holo-IscR, while the Type 2 motifs are recognised by both holo- and apo- forms [76,80].

441

442 Analysis of the promoter region of *dctA* revealed the presence of a putative Type 2 IscR-
443 binding site (ATAACCTTACAAGACCTGTGGTTTTT) [80] located 10 bp downstream of
444 the transcription start site of *dctA* (Fig 7A). Both the Succ⁺ mutants *dctA^{mut1}*, *dctA^{mut2}*
445 carried SNPs within this DNA motif. This motif is also conserved in *E. coli* MG1655 (Fig
446 7A) and a similar SNP, that stimulated *dctA* transcription and succinate utilisation, was
447 previously identified in the *E. coli* B strain REL606 [81] (Figure 7A).

448

449 To investigate which of the apo/holo-forms of IscR was repressing succinate utilisation in
450 *Salmonella*, we constructed a plasmid expressing an IscR variant carrying three Cys→Ala
451 substitutions (IscR^{3CA}, Cys_{92,98,104}→Ala_{92,98,104}) that prevent the binding of [Fe₂-S₂] to IscR,
452 and maintain the apo-form of the protein [82,83]. The plasmid-borne expression of both
453 IscR and IscR^{3CA} complemented the $\Delta iscR$ deletion and suppressed the Succ⁺ phenotype
454 (Figure 7 E), indicating that both apo- and holo- IscR repress succinate utilisation.

455

456 Collectively, these results demonstrated that IscR plays a critical role in the repression of
457 *dctA* and in the inhibition of succinate utilisation. The apo-IscR represses succinate
458 utilisation, suggesting that IscR represses *dctA* expression by binding the putative Type 2
459 DNA motif identified downstream of the *dctA* promoter. The finding of *dctA*-stimulating
460 SNPs in this motif supports our hypothesis, and it is possible that the binding of IscR
461 downstream of the promoter acts as a “roadblock” that inhibits *dctA* transcription, as
462 proposed for the repression of *mgtC* by PhoP [84]. However, we cannot rule out that the
463 *dctA* repression by IscR is indirect with the *dctA*^{mut1} and *dctA*^{mut2} mutations stimulating
464 *dctA* transcription by another mechanism. Further study is required to understand the
465 IscR-driven repression of *dctA* at the mechanistic level.

466

467 Our data show that the sole de-repression of *dctA* expression mutations is sufficient to
468 stimulate *Salmonella* growth with succinate, consistent with a previous report [16].
469 However, *dctA* de-repression was only observed in the *dctA*^{mut1}, *dctA*^{mut2} and Δ *iscR*
470 mutants, raising the question of whether DctA-driven succinate uptake is the key limiting
471 factor for rapid growth of *Salmonella* in M9+Succ or whether overexpression of the DctA
472 transporter, in its role of succinate co-sensor, may indirectly boost the expression of other
473 limiting succinate utilisation genes.

474

475 **Succinate utilisation is inhibited by RbsR and FliST via RpoS**

476

477 Factors that modulate RpoS expression, stability or activity are likely to control succinate
478 utilisation in *Salmonella*. For example, the inactivation of the anti-adaptor IraP stimulates
479 succinate utilisation by increasing RssB-facilitated proteolysis of RpoS by the ClpXP
480 protease [16,85,86]. In our genetic screens we found that succinate utilisation was
481 stimulated by the absence of IraP, CspC, RbsR and FliST and by increased expression of
482 OxyS.

483

484 To assess RpoS levels in the corresponding Succ⁺ mutants, we used Western blot
485 detection (Supplementary Fig S7A). The RpoS levels in the Δ *cspC*, Δ *fliST*, *oxyR*^{mut}
486 mutants were similar to the WT strain, while lower levels of RpoS were observed in the
487 Δ *iraP* and Δ *rbsR* mutants. We confirmed the role of RbsR in RpoS activation by
488 complementing the Δ *rbsR* mutation with the *prbsR* plasmid, revealing that inactivation of
489 RbsR reduced RpoS abundance in exponential and early stationary phases, but not in
490 stationary phase (Fig 8A, Supplementary Fig S7B). During the characterisation of the

491 Succ⁺ mutants, we noticed that the RbsR null strain was impaired in its capacity to form
492 red, dry and rough colonies (RDAR), another RpoS-dependent phenotype of *Salmonella*
493 [87]. The RDAR morphotype was restored in the $\Delta rbsR$ mutant by complementation with
494 the plasmid *prbsR* (Fig 8B). We observed that the plasmid-borne overexpression of RpoS
495 in the RbsR null mutant totally abolished the Succ⁺ phenotype, indicating that RbsR
496 represses succinate utilisation *via* the activation of RpoS (Fig 8C).

497

498 RbsR is a LacI-type transcriptional regulator that inhibits the transcription of the ribose
499 utilisation operon (*rbsDACBKR*) in the absence of ribose [88]. To investigate whether
500 RbsR stimulated *rpoS* transcription, we used a chromosomal transcriptional GFP reporter
501 fusion, where the *gfp*⁺ gene (including its SD sequence) was inserted downstream of the
502 main transcription start site of the *rpoS* locus (Fig S7C). Similar GFP levels were observed
503 in the WT and the $\Delta rbsR$ strains grown to either exponential, early stationary or stationary
504 phase (Fig S7D).

505

506 Taken together, our findings show that RbsR acts as a pleiotropic regulator in *Salmonella*,
507 controlling growth with succinate and the RDAR morphotype, *via* the positive regulation of
508 *rpoS*. RbsR does not directly stimulate *rpoS* promoter activity and we propose an indirect
509 RbsR-driven activation of RpoS at the post-transcriptional or the post-translational level. In
510 line with this hypothesis, it was recently observed that RpoS is repressed at the post-
511 transcriptional level, when *rbsD*, a gene controlled by RbsR, is over-expressed in *E. coli*
512 [89].

513

514 Our work also revealed that the two flagellar chaperones FliS [90] and FliT [91] control
515 succinate utilisation (Fig 3, Fig S2B), suggesting a link between the control of the flagellar
516 machinery and *Salmonella* central carbon metabolism. In the $\Delta fliST$ mutant, RpoS
517 overexpression totally suppressed the Succ⁺ phenotype (Fig 8C) indicating that the
518 regulation is RpoS-dependent. However, Western blots did not show reduced levels of
519 RpoS in the FliST null mutant (Fig S7A). It remains unclear how these protein chaperones
520 inhibit succinate utilisation, and whether FliS and FliT are capable of stimulating the
521 expression or the activity of RpoS.

522

523 **Anti-Shine-Dalgarno mutations and sub-inhibitory concentration of chloramphenicol**
524 **boost succinate utilisation**

525

526 We identified a novel class of mutations that boost succinate utilisation by altering the anti-
527 Shine-Dalgarno sequence (aSD) of the 16S ribosomal RNAs (rRNAs). Specifically, aSD
528 SNPs in *rrsA* and *rrsH* genes that encode two of the seven 16S rRNAs present in
529 *Salmonella* genomes [92] were found (alleles *rrsA^{mut}* and *rrsH^{mut}*, Fig 9A). Mature 16S
530 rRNAs are assembled with ribosomal proteins to form the 30S ribosomal subunits that
531 initiate mRNA translation [93,94]. Each 16S rRNA 3'-end carries an aSD motif
532 (CCUCCUU) that base-pairs with the Shine-Dalgarno sequence (SD) on mRNA, promoting
533 translational initiation at the start codon [95,96].

534

535 The SNPs carried by the *rrsA^{mut}* and *rrsH^{mut}* strains dramatically stimulated growth of
536 *Salmonella* in M9+Succ, reducing the lag time to ~7 hours. When *E. coli* grows under
537 nutrient limitation, the relative transcription of the *rrnH* rRNA operon increases and the
538 resulting pool of RrsH-containing ribosomes can modulate the stress response by
539 stimulating RpoS translation or stability [97]. Therefore, we reasoned that the aSD
540 mutations may totally inactivate the rRNAs resulting in the reduction of RpoS expression.
541 However, deletion of the *rrsA* and *rrsH* loci did not result in a Succ⁺ phenotype (Fig 9C).
542 The plasmid-borne expression of *rpoS* only marginally increased the lag time of the *rrsA^{mut}*
543 and *rrsH^{mut}* mutant strains, indicating that the mutations in the 16S rRNAs stimulate
544 succinate utilisation, at least partially, in a RpoS-independent manner (Fig 9D-E).

545

546 In *E. coli*, 16S rRNAs that carry a mutated aSD motif are processed and assembled into
547 functional 30S subunits, which can initiate translation at the correct start codon [98]. This
548 suggests that the mutated 16S rRNA RrsA^{mut} and RrsH^{mut} are assembled normally, and
549 the presence of the resulting altered ribosome stimulates *Salmonella* growth upon
550 succinate.

551

552 The aSD mutations prompted us to experiment with a translational inhibitor. We observed
553 that subinhibitory concentrations of chloramphenicol (Cm) stimulated growth of 4/74 WT
554 upon succinate (Fig 9F). The shortest lag time (~8 hours) was observed at a Cm
555 concentration of 1.5 µg/mL. Addition of Cm caused a similar level of growth stimulation for
556 *S. Enteritidis* strain P125109 (Supplementary Fig S8A), indicating that the phenomenon is
557 conserved in other *Salmonella* serovars.

558

559 Cm targets the 50S ribosome subunits to block translation [99]. Subinhibitory
560 concentrations of this antibiotic prevent the RelA-mediated synthesis of the alarmone
561 (p)ppGpp, the key signal molecule of the stringent response [100]. During amino acid
562 starvation, (p)ppGpp accumulation is known to promote the transcription, translation and
563 stability of RpoS [51], raising the possibility that the aSD mutations and Cm stimulate
564 succinate utilisation directly through RpoS attenuation. Tetracycline (Tc) and other
565 translation-inhibiting antibiotics also inhibit (p)ppGpp synthesis in *E. coli* [101], prompting
566 us to test subinhibitory concentrations of Tc hydrochloride (1 and 2 µg/mL). However, Tc
567 did not stimulate the growth of 4/74 at the concentrations tested (Fig S8B), suggesting that
568 Cm does not reduce RpoS expression, *via* the inhibition of the stringent response.

569

570 Taken together, our findings suggest that the impairment of the ribosomal machinery by
571 aSD mutations or by the presence of chloramphenicol impose a translational stress that
572 stimulates genes involved in succinate utilisation. In line with this hypothesis, the
573 inactivation of the translational elongation factor EF-P [102,103] also stimulated the growth
574 of *Salmonella* upon succinate [16]. However, the link between protein biosynthesis
575 impairment and the stimulation of succinate utilisation remains enigmatic. Further work will
576 be required to decipher the regulatory mechanism that underpins this phenomenon.

577

578 **Perspective**

579

580 During infection, *Salmonella* and other pathogens face a metabolic dilemma between self-
581 preservation and nutritional competence that is exemplified by succinate utilisation
582 [1,104,105]. The RpoS master regulator functions as a double-edged sword, activating
583 critical resistance mechanisms required for survival in the host [19,20], and reducing
584 nutritional capacity by repressing the utilisation of several infection-relevant C-sources,
585 including succinate [22,25].

586

587 Our genetic dissection revealed that RbsR, PNPase, Hfq and sRNAs modulate succinate
588 metabolic capacity, *via* the fine-tuned control of RpoS. Furthermore, succinate utilisation is
589 inhibited by the RpoS-independent CspC and IscR systems. These distinct regulatory
590 mechanisms are likely to adjust *Salmonella* metabolism during the journey of the pathogen
591 through the host; from the colonisation of the gastrointestinal tract to intra-macrophage
592 replication. We showed that the sRNA OxyS antagonises CspC-dependent inhibition (Fig 5
593 & Fig 6). Because OxyS is induced by oxidative stress, our findings raise the possibility
594 that the reactive oxygen species produced in the inflamed gut [106,107] stimulate
595 *Salmonella* growth upon microbiota-derived succinate in this niche [3,5].

596

597 Despite, the abundance of succinate within infected macrophages [11], the intracellular
598 proliferation of *Salmonella* does not require succinate catabolic genes [14]. The high levels
599 of intra-macrophage expression of the *iscR* [108] and *rpoS* [108,109] lead us to propose
600 that the DctA-driven uptake and catabolism of succinate are strongly repressed in this
601 cellular niche. Because succinate triggers the induction of *Salmonella* genes associated
602 with survival and virulence within macrophages [13], we speculate that succinate utilisation
603 is comprehensively repressed to prevent depletion of this critical signalling molecule from
604 the intracellular niche.

605

606 Pioneering work from the 1960s established that constitutive succinate utilisation ablated
607 *Salmonella* virulence in the murine infection model [110,111], giving the first suggestion
608 that tight regulation of succinate utilisation was critical for pathogenesis. Six decades later
609 we have revealed that multiple systems control the utilisation of succinate, making the
610 catabolism of succinate responsive to various environmental stimuli (Fig 10). We propose
611 that the redundant regulatory systems ensure that *Salmonella* only utilises succinate “at
612 the right place and at the right time” during infection.

613 **Materials and Methods**

614

615 **Bacterial strains and growth conditions**

616

617 Precise details of all the chemicals, reagents, DNA oligonucleotides (primers), plasmids
618 and bacterial strains used in this study are listed in Supplementary Resource Table S1.
619 The *Salmonella* mutant strains were all derivatives of *Salmonella enterica* serovar
620 Typhimurium strain 4/74 [112]. Strain 4/74 is now available from the UK National
621 Collection of Type Cultures
622 (<https://www.culturecollections.org.uk/products/bacteria/index.jsp>) as NCTC 14672. All the
623 nucleotide coordinates given for 4/74-derived strains correspond to the published genome:
624 GenBank CP002487.1 [35]. *Escherichia coli* strains Top10 (Invitrogen) and S17-1 λ pir
625 [113] were used as hosts for the cloning procedures.

626

627 Unless otherwise specified, bacteria were grown at 37°C with aeration (orbital shaking 220
628 rpm) in Lennox Broth (LB: 10 g/L BD Tryptone, 5 g/L BD Yeast Extract, 5 g/L NaCl), LBO
629 10 g/L BD Tryptone, 5 g/L BD Yeast Extract) or in M9 minimal medium [114], prepared
630 with M9 Salts, 2 mM MgSO₄, 0.1 mM CaCl₂ and 40 mM sodium succinate dibasic
631 hexahydrate (succinate) or 40 mM glycerol + 10 mM Succinate, as sole C-sources
632 (henceforth, media M9+Succ and M9+Gly+Succ). Agar plates were prepared with the
633 same media, solidified with 1.5% BD Bacto agar. When required, 10-100 µM of FeCl₃ were
634 added to the M9 media.

635

636 To seed the M9-derived media of all the experiments, stationary phase pre-cultures were
637 prepared by inoculating isolated colonies into 5 mL LB (in 30 mL Universal glass tubes)
638 and the cultures were incubated for 6-20 hours at 37°C with aeration. Bacteria were
639 harvested by centrifugation, washed once, and Optical Density at 600 nm (OD₆₀₀) was
640 adjusted to 1 with the minimal medium used for the cultures, or with 1 X Phosphate-
641 Buffered Saline (PBS) to generate a standardised inoculum. Subsequently, bacteria were
642 grown aerobically in conical flasks (topped with aluminium foil) or in Greiner 50 mL plastic
643 tubes (with lids slightly open to allow gaseous exchange). Washed bacteria from the pre-
644 cultures were inoculated as a 1:100 dilution to give a starting OD₆₀₀ of 0.01 (~10⁷
645 CFU/mL), in a final medium volume corresponding to 10% of the flask/tube capacity, to
646 ensure optimal oxygenation by shaking.

647

648 For growth curves in 96-well microplates (Greiner #655180), bacteria grown beforehand
649 for ~6 hours in LB, were washed with the minimal medium used for the cultures, or with
650 PBS, and inoculated to give a starting OD₆₀₀ of 0.01 in 200 µL of medium *per well*. The
651 microplates were incubated at 37°C with orbital shaking (500 rpm), in a FLUOstar Omega
652 plate reader (BMG Labtech), and the OD₆₀₀ was monitored every 15-30 min, using the
653 appropriate growth medium as blank.

654

655 When required, antibiotics were added as follows: 50 µg/mL kanamycin monosulfate (Km),
656 100 µg/mL Ampicillin sodium (Ap), 25 µg/mL tetracycline hydrochloride (Tc), 20 µg/mL
657 gentamicin sulfate (Gm) and 25 µg/mL chloramphenicol (Cm).

658

659 For strains carrying the *tetR-P_{tetA}* module, the *P_{tetA}* promoter was induced by adding 500
660 ng/mL of anhydrotetracycline hydrochloride (AHT, from a 1 mg/mL stock solubilised in
661 methanol). The same volume of methanol was added to the mock-induced cultures. To
662 stimulate expression of genes controlled by the *P_{BAD}* promoter (*e.g.* in plasmid pWRG99),
663 0.2 % L-(+)-arabinose was added to the culture. For the strains carrying the plasmid pSW-
664 2 [115], the *P_m* promoter was induced by adding 1 mM *m*-toluate (500 mM stock titrated
665 with NaOH to pH 8.0).

666

667 **Bacterial transformation and Tn5 mutagenesis**

668

669 Chemically-competent *E. coli* were prepared and transformed as previously published
670 [116]. Electrocompetent cells were prepared with *Salmonella* cultures grown in salt free
671 LBO medium and were electroporated, as described previously [117]. After recovery in LB
672 at 37°C (30°C for temperature-sensitive plasmids) transformation reactions were spread
673 on selective LB agar plates and transformants were obtained after incubation at 30°C or
674 37°C.

675

676 For the Tn5 transposon mutagenesis, ultra-competent *Salmonella* were prepared from
677 LBO cultures grown at 45°C, as previously reported [117,118]. The λ *pir*-dependent
678 plasmid pRL27 [119], that encodes the Tn5 transposase gene (*tnp*) and the mini Tn5-
679 *oriR6K-Km^R* transposon (Tn5), was used to generate the *Salmonella* Tn5 libraries, as
680 follows: 50 µL of ultra-competent *Salmonella* were electroporated with 500 ng of the non-
681 replicating Tn5 delivery plasmid pRL27. After 1 hour recovery in LB the transformation
682 reactions containing the Tn5-carrying *Salmonella* were washed in PBS or minimal media

683 and 1% of transformations was spread on LB Km plates to estimate the size of the
684 resulting Tn5 library. The remainder of the Tn5 libraries were stored for further
685 experiments.
686

687 Cloning procedures

688

689 Enzymes, buffer and kits used are listed in Supplementary Resource Table S1. DNA
690 manipulations were carried out according to standard protocols [114]. DNA fragment were
691 purified from enzymatic reactions or from agarose gel using the Bioline ISOLATE II PCR
692 and Gel Kit. Plasmids were extracted with the Bioline ISOLATE II Plasmid Mini Kit.
693 Genomic DNA (gDNA) was isolated from 0.5-1 mL of stationary phase cultures with the
694 Zymo Quick DNA Universal Kit.

695

696 For PCR, DNA was amplified with Phusion High Fidelity DNA polymerase, template DNA
697 and 0.5 μ M primers, in the presence of 3 % Dimethyl Sulfoxide and 1 M betaine. For
698 plasmid/strain verifications by Sanger sequencing, PCR reactions were carried out from
699 bacterial colonies with MyTaq Red Mix 2 X and PCR fragment were Sanger sequenced
700 with the appropriate primers (Lightrun service, Eurofins Genomics).

701

702 DNA digestion/ligation procedures or the restriction-free “PCR cloning” technique [120]
703 were used to insert DNA fragments into the plasmids pEMG [115], pJV300 (pP_L)[67] and
704 pXG10-SF [121]. *E. coli* Top10 was used as host for the construction of pXG10-SF and
705 pP_L derived plasmids, while S17-1 λ pir was used for pEMG derivatives.

706

707 The construction of each plasmid is detailed in Supplementary Resource Table S1. For
708 complementation experiments, the genes of interest (including their native ribosome
709 binding site) were PCR-amplified from 4/74 gDNA and were cloned between the NsiI and
710 XbaI sites of the low copy plasmid pXG10-SF, resulting in plasmids *phfQ* (pNAW45), *prpoS*
711 (pNAW95), *piraP* (pNAW98), *pfliST* (pNAW94), *prbsR* (pNAW93), *piscR* (pNAW96) and
712 *pcspC* (pNAW92). For the construction of the *piscR*^{3CA} plasmid (pNAW97, carrying three
713 Cys→Ala substitution at positions 92, 98 and 104 in *IscR*), two fragments carrying the
714 appropriate mutations were first amplified with primer pairs NW_461/NW_467 and
715 NW_462/NW_466 and the resulting amplicons were fused by overlap extension PCR [122]
716 before insertion into pXG10-SF. In all these plasmids, the genes of interest were under the
717 control of the strong constitutive promoter *P_{L tetO-1}* [123]. For the construction of *ppnp*
718 (pNAW256), the *pnp* gene and its promoter region (including *sraG*) were amplified and
719 inserted between the XhoI and XbaI sites of pXG10-SF. In the resulting plasmid, *pnp*
720 expression was controlled by its native promoter. For the construction of *poxyS* (pP_L-*oxyS*,
721 pNAW255), *oxyS* was PCR amplified and inserted by PCR cloning downstream of

722 constitutive $P_{L\ lacO-1}$ promoter of the pP_L vector, as described earlier [124]. The plasmid-
723 borne translational fusion $yobF::_{sgfp}$ ($pyobF::_{sgfp}$, pNAW258) was constructed by cloning
724 the 5'-UTR of *yobF* and its 31 first codons in frame with the *sgfp* gene of pXG10-SF, as
725 previously described [121].

726

727 Plasmid site-directed mutagenesis [125] was used to introduce the CC→GG mutation in
728 the pP_L-oxyS: complementary primers NW_1022 and NW_1023, carrying the mutations
729 were annealed and elongated by PCR for 10 cycles. Fifty nanograms of plasmid poxyS
730 (pP_L-oxyS, pNAW255) were added to the reaction and the PCR reaction was resumed for
731 25 cycles. After DpnI treatment and transformation in *E. coli* Top10, the mutated plasmids
732 pP_L-oxyS^{GG} (pNAW259) was obtained.

733

734 For the construction of the empty vector pNAW125 (pXG10-SF lacking the $lacZ^{186}::_{sgfp}$
735 fragment), a 3.5 kb fragment was PCR-amplified from pXG10-SF with the primer pair
736 NW_348/NW_565, the resulting fragment was digested with NsiI and self-ligated.

737

738 All the pXG10-SF, pEMG and pP_L derived plasmids were verified by Sanger sequencing:
739 primers pXG10_R2 and pZE-CAT were used for plasmid pXG10-SF, primers M13_
740 40_long and M13_Rev_long for plasmid pEMG and primer pZE-A for plasmid pP_L.

741

742 **Genome editing techniques**

743

744 The λ *red* recombination methodology was used to insert or delete genes in the
745 *Salmonella* chromosome, using the heat-inducible λ *red* plasmid pSIM5-*tet* [127].
746 *Salmonella* carrying the pSIM5-*tet* were grown in LBO at 30°C and electrocompetent
747 bacteria were prepared after a 15 minute heat shock at 42°C, as previously described
748 [117,128]. PCR fragments carrying a resistance gene were PCR-amplified from the
749 template plasmids pKD4, pKD3, pNAW52, pNAW55 or pNAW62 [117,126].
750 Electrocompetent bacteria (50 μ L) were transformed with 500-3000 ng of the PCR
751 fragments, and recombinants were selected on LB agar plates that contained the
752 appropriate antibiotics.

753

754 The deletions/insertions linked to a selective marker and the Tn5 insertions were
755 transduced to *S. Typhimurium* strains using the P22 HT 105/1 *int-201* (P22 HT)
756 transducing phage, as previously reported [129,130].

757

758 When required, antibiotic resistance cassettes flanked by FLP recognition target sites (*frt*),
759 were removed from the *Salmonella* chromosome with the FLP recombinase-expressing
760 plasmid pCP20 [131]. Subsequently, the temperature sensitive plasmid pCP20 plasmid
761 was eliminated by a single passage at 42°C.

762

763 The construction of each strain is detailed in Supplementary Resource Table S1. The
764 marked mutations $\Delta rpoS::aph$, $\Delta hfq::aph$, $\Delta rybB::aph$, $\Delta pnp::cat$ (*pnp-539*) and $\Delta arcA::aph$
765 were transduced from published 4/74 and SL1344 derivative strains. For the transduction
766 of the $\Delta hfq::aph$ mutation, the donor strain JH3584 was first complemented with the
767 plasmid *phfq* (pNAW45), because Hfq is required for P22 transduction [67].

768

769 The 4/74 *tetR-P_{tetA}-dctA* strain was constructed according to the principle described by
770 Schulte and colleagues [132]. The promoter and the 5'-UTR of *dctA* (coordinates
771 3812883-3812972) were replaced by a *frt-aph-frt-tetR-P_{tetA}* module from plasmid pNAW55.
772 In the resulting strain, *dctA* has the *tetA* ribosome binding site and is controlled by the
773 AHT-inducible *P_{tetA}* promoter.

774

775 To measure *rpoS* expression, a chromosomal transcriptional *rpoS-gfp⁺* fusion was
776 constructed as follows: the *gfp⁺-frt-aph-frt* module of pNAW52 (including the *gfp⁺* SD) was
777 inserted after the main *rpoS* transcription start site (TSS), previously mapped at the
778 coordinate 3089613 on the 4/74 chromosome [133].

779

780 To measure *dctA* expression, a chromosomal transcriptional/translational *dctA::_{sf}gfp* fusion
781 was constructed: the flexible amino acid linker GSAGSAAGSGEF and the sequence
782 encoding for superfolder GFP (*_{sf}gfp*) were fused to the *dctA* C-term, using a *_{sf}gfp-frt-aph-frt*
783 module amplified from pNAW62 [117].

784

785 For complementation in *oxyS* and *rpoS* null mutants, a single copy of these genes was
786 inserted in a non-transcribed chromosomal locus in two steps: first, an antibiotic cassette
787 was inserted upstream of the *oxyS* or *rpoS* promoters, coordinates 4364521 and 3089777,
788 respectively. Then, the *aph-oxyS* and the *cat-rpoS* modules were PCR-amplified from the
789 resulting strains and inserted into the non-transcribed pseudogene *STM474_1565*
790 (between coordinates 1585970-1586170 on the 4/74 chromosome) [117]. The
791 *STM474_1565* gene is also known as *STM1553* or *SL1344_1483*.

792

793 For scarless transfer of *rrsA^{mut}* and *rrsH^{mut}* mutations located in the 16S rRNA genes, the
794 two step λ *red* recombination-based methodology described by Blank and colleagues was
795 used [134]. The *rrsA* and *rrsH* genes (including their promoters) were replaced by a I-SceI-
796 *aph* module, amplified from plasmid pKD4-I-SceI [129]. The mutations were transduced in
797 4/74 WT, yielding the strains $\Delta rrsA::(I-SceI-aph)$ and $\Delta rrsA::(I-SceI-aph)$. The two strains
798 were transformed with the λ *red* plasmid pWRG99, expressing the I-SceI nuclease in the
799 presence of AHT [134]. Electro-competent cells were prepared with the two
800 *Salmonella*+pWRG99 strains in the presence of arabinose, as described above.
801 Competent bacteria were electroporated with 2 μ g of the *rrsA^{mut}* or the *rrsH^{mut}* fragments,
802 obtained by PCR from spontaneous mutants SNW245 (*rrsA^{mut}*) and SNW246 (*rrsH^{mut}*).
803 Replacement of the I-SceI-*aph* module by the corresponding *rrs* mutated PCR fragment
804 was selected on LB agar supplemented with Ap and AHT at 30°C. The *rrsA^{mut}* or *rrsH^{mut}*
805 insertions were confirmed by PCR and Sanger sequencing and the temperature-sensitive
806 pWRG99 plasmid was eliminated by a passage at 42°C.

807

808 For other scarless genome editing procedures, the pEMG-based allele exchange
809 technique [115] was used as previously described [129,135]. For the transfer of the
810 *dctA^{mut1}*, *dctA^{mut2}* and *oxyR^{mut}* mutations, fragments encompassing the mutations and the
811 ~500 bp flanking regions were PCR-amplified from the corresponding spontaneous *Succ⁺*
812 mutants. For the construction of the *oxyS^{GG}* mutant, two fragments flanking the mutations
813 were PCR amplified with primer pairs NW_1021/NW_1022 and NW_1023/NW_1024. The
814 two amplicons carrying the CC→GG mutation on one of their extremities were fused by
815 overlap extension PCR. All the PCR fragments carrying the mutations were inserted by
816 digestion/ligation between the EcoRI and BamHI sites of the suicide plasmid pEMG and *E.*
817 *coli* S17-1 λ *pir* was transformed with the resulting ligation reactions. The resulting suicide
818 plasmids were mobilised into the recipient *Salmonella* by conjugation and recombinants
819 were selected on M9-glucose agar plates containing Km. Merodiploid resolution was
820 carried out with the pSW-2 plasmid, as previously described [129]. The relevant mutations
821 were confirmed in Km^S candidates by PCR and Sanger sequencing. Finally, the unstable
822 pSW-2 plasmid was eliminated by 2-3 passages on LB.

823

824 **Experimental evolution to select *Succ⁺* mutants**

825

826 A 4/74 strain with an additional *rpoS* copy inserted in the *STM474_1565* pseudogene
827 (strain *rpoS*^{2X}, SNW226, Cm^R) was transformed with pRL27 and ten libraries of
828 approximately 10,000 Tn5 mutants were grown aerobically in 25 mL of M9+Succ
829 containing Cm and Km in ten 250 mL conical flasks. After 48 hours incubation at 37°C, the
830 cultures were spread on LB + Km plates and isolated colonies were passaged twice on LB
831 agar. Growth on M9+Succ plates was assessed for >10 isolates *per* library. The Tn5
832 insertions from fast-growing colonies (Succ⁺ phenotype) were P22-transduced into 4/74
833 WT, and the Succ⁺ status of the transductants was verified.

834

835 For the isolation of Succ⁺ spontaneous 4/74 mutants, bacteria obtained from stationary
836 phase LB cultures were washed with PBS and the OD₆₀₀ was adjusted to 0.1 (~10⁸
837 CFU/mL). Approximately 10⁷ CFU (100 µL) were spread on M9+Succ agar and the plates
838 were incubated at 37°C, until Succ⁺ large colonies were visible (3-4 days). Alternatively,
839 spontaneous mutants were obtained from liquid M9+Succ cultures (25 mL), inoculated
840 with ~100 *Salmonella*. The cultures were grown aerobically at 37°C, until substantial
841 growth was observed (typically after 3 days incubation) and the cultures were spread on
842 LB agar plates. All the presumed Succ⁺ spontaneous mutants were passaged twice on LB
843 plates before confirming the Succ⁺ phenotype on M9+Succ agar plates. The *rpoS* positive
844 status (*rpoS*⁺) of each mutant was tested by phenotypic assays (see below) and confirmed
845 by PCR and Sanger sequencing, using primers NW_403, NW_252 and NW_252.

846

847 The genomes of a collection of *rpoS*⁺ Succ⁺ mutants were sequenced by the Illumina
848 whole genome sequencing service of MicrobesNG (Birmingham, UK). Mutations were
849 identified using the VarCap workflow [136] available on Galaxy
850 (<http://galaxy.csb.univie.ac.at:8080>), using the published 4/74 genome as reference. The
851 identified mutations were confirmed by PCR and Sanger sequencing, and were transferred
852 into 4/74 WT using the two scarless genome editing techniques described above. After
853 transfer, the Succ⁺ phenotype of all genome-edited mutants was confirmed.

854

855 **Phenotypic characterisation of the Succ⁺ mutants**

856

857 Phenotypes linked to the *rpoS* status were tested for each of the Succ⁺ Tn5 or Succ⁺
858 spontaneous mutants. The RpoS-dependent catalase activity was assessed with hydrogen
859 peroxide directly on colonies or with stationary phase LB cultures, as described earlier
860 [137,138]. The RpoS-dependent RDAR (red, dry and rough) morphotype [87] was tested

861 by adding 2 μ L of a stationary phase LB cultures on LBO agar plates containing 40 μ g/mL
862 of Congo Red. The RDAR morphotype was observed after at least 3 days of incubation at
863 room temperature.

864

865 **Mapping of Tn5 insertion sites**

866

867 The Tn5 insertion sites of the Succ⁺ mutants were mapped by an arbitrary PCR approach
868 [139]. For each Tn5 mutant, the arbitrary PCRs were carried out directly from colonies with
869 the primer pair NW_319/NW_320 (0.5 μ M each) and MyTaq Red Mix 2 X in a final volume
870 of 20 μ L. The arbitrary PCR conditions were: 95°C 120 sec; 6 X [95°C 15 sec 30°C; 30 sec
871 ; 72°C 90 sec]; 30 X [95°C 15 sec ; 50°C 30 sec ; 72°C 90 sec] ; 72°C 300 sec ; 4°C. The
872 amplicons were purified on column and eluted in 20 μ L of water. For the nested PCRs, 2
873 μ L of the arbitrary PCR products were used as template and mixed with primer pair
874 NW_318/NW_321 (0.5 μ M each) and MyTaq Red Mix 2 X in a final volume of 40 μ L. The
875 second PCR conditions were: 95°C 120 sec; 30 X [95°C 15 sec; 50°C 30 sec ; 72°C 90
876 sec]; 72°C 300 sec. The PCR products were separated by electrophoresis on a 1 %
877 agarose gel containing Midori Green for DNA UV-visualization. The most prominent DNA
878 bands were excised, the DNA was purified and Sanger-sequenced with primer NW_318.
879 Insertions were mapped by BLAST, using the 4/74 genome as reference.

880

881 **Quantification of GFP fluorescence intensity**

882

883 Strains carrying the chromosomal fusion *rpoS-gfp*⁺ or the plasmid-borne *yobF::_{st}gfp*
884 translational fusion were grown in the indicated conditions in biological triplicates and
885 bacteria were harvested by centrifugation and re-suspended in the same volume of PBS.
886 The GFP signal was measured with a FLUOStar Omega plate reader (BMG Labtech) with
887 200 μ L of bacterial suspension *per* well in black microplates (Greiner #655090). For each
888 strain, the PBS background fluorescence was subtracted from the GFP signal (in arbitrary
889 unit [a.u.]). The fluorescence values were divided by the OD₆₀₀ of the cell suspensions.
890 The fluorescence background of a WT unlabeled strain (carrying the empty plasmid
891 pNAW125, when required) was measured similarly, and was subtracted from the
892 fluorescence signal of the GFP-labelled strain. For each strain the GFP fluorescence
893 intensity is represented as absolute values (GFP fluorescence intensity/OD₆₀₀ [a.u.]) or as
894 a relative GFP fluorescence intensity (in %).

895

896 To measure the activity of the *dctA::sfgfp* chromosomal fusion, bacteria were grown in
897 M9+Gly+Succ to OD₆₀₀ 0.5-1. Cells were harvested and re-suspended in PBS, prior to
898 fixation with 4% paraformaldehyde and washes with PBS [140]. To measure the GFP
899 fluorescence intensity in all the strains carrying *dctA::sfgfp*, the IntelliCyt iQue® Screener
900 PLUS (Sartorius) was used. To quantify the *dctA::sfgfp* activity more precisely in the WT,
901 *dctA^{mut1}*, *dctA^{mut2}*, Δ *iscR* and Δ *rpoS* genetic backgrounds, bacteria were grown in
902 biological triplicates and were fixed with paraformaldehyde. The FITC-H GFP fluorescence
903 intensity (median of the population) was measured using a FACSCanto™ II flow cytometer
904 (BD Biosciences). The fluorescence background of a WT unlabelled strain was subtracted
905 from the fluorescence intensity of each *dctA::sfgfp* carrying strain. The data are
906 represented as the GFP fluorescence intensity of each mutant, relative to the intensity of
907 the WT isogenic strain (%). All flow cytometry data were analysed using the FlowJo™
908 software (BD Biosciences).

909

910 For fluorescence microscopy, the *dctA::sfgfp*-carrying strains were grown in M9+Succ or
911 M9+Gly+Succ and bacteria were immobilised in PBS solidified with 0.75% low melting
912 point agarose. Pictures were taken with the EVOS FL cell imaging system (Thermo
913 Fisher), as previously described [124].

914

915 **RpoS detection by Western blotting**

916

917 The strains of interest were grown in the indicated condition, and bacteria (~10⁹ CFU,
918 estimated by OD₆₀₀) were pelleted by centrifugation and stored at -80°C. Bacteria were re-
919 suspended in 100 µL of PBS and 10 µL of the cell suspensions were mixed with 990 µL of
920 PBS to measure the OD₆₀₀ 1/100 of each suspension. Bacteria were lysed by adding 100
921 µL Laemmli Buffer 2 X [120 mM Tris-HCl pH 6.8, 4% (wt/vol) SDS, 20% (vol/vol) glycerol,
922 Bromophenol blue 0.02% (wt/vol)] and 10 µL β-mercaptoethanol (5% vol/vol final). The
923 lysates were boiled for 15 min, chilled on ice for 1 min and spun down for 5 min at 4 °C
924 (14,000 rpm). Bacterial extracts were separated by SDS polyacrylamide gel
925 electrophoresis and the proteins RpoS and DNaK were detected by Western Blotting, as
926 described earlier [128]. The volume of protein extract loaded (~10 µL) on the SDS 10%
927 polyacrylamide gel was normalised by the OD₆₀₀ of the bacterial suspensions prior to lysis.

928

929 Catalogue numbers of all antibodies are listed in Supplementary Resource Table S1. The
930 primary antibodies, Anti-*E. coli* RNA Sigma S Antibody (diluted 1:5,000) and anti-DnaK

931 mAb 8E2/2 (diluted 1:10,000), were used for the detection of RpoS and DnaK (loading
932 control), respectively. For detection, the secondary antibody Goat anti-mouse IgG (H + L)-
933 HRP (diluted 1:2,500) and the Pierce ECL Western blotting substrate were used. The
934 chemiluminescent reaction was detected with the ImageQuant LAS 4000 imaging system
935 (GE Healthcare Life Sciences).

936

937 **OxyS detection by Northern blotting**

938

939 The WT, $\Delta oxyR$ and $oxyR^{mut}$ strains were grown in 25 mL of LB to $OD_{600} = 1$ and the
940 cultures were split in two 10 mL subcultures. For each strain, hydrogen peroxide (H_2O_2 , 2
941 mM) was added to one of the subcultures. After 30 min at 37 °C, cellular RNA transcription
942 and degradation processes were stopped by adding 4 mL of ice-cold STOP solution (95%
943 ethanol + 5% acid phenol) to the 10 mL cultures. After a 30 min incubation on ice, bacteria
944 were pelleted by centrifugation and total RNA was extracted with Trizol, as described
945 previously [124].

946

947 Probe synthesis and OxyS sRNA detection by Digoxigenin (DIG)-based Northern blotting
948 were carried out with the DIG Northern Starter Kit, according to the DIG Application
949 Manual for Filter Hybridization (Roche) and a previous study [124]. Briefly, heat-denatured
950 RNA (2.5 μ g) was separated on an 8.3 M urea, 7% polyacrylamide gel in TBE 1X. RNA
951 was transferred to a positively charged nylon membrane with the Bio-Rad Semi Dry
952 transfer system (#170-3940). RNA was UV-crosslinked to the membrane before
953 hybridization with the DIG-anti-OxyS probe in DIG Easy Hyb buffer at 68°C for 20 hours.
954 The membrane was washed and the OxyS transcripts were detected using the Anti-
955 Digoxigenin antibody and the CDP-*Star* substrate. Finally, the chemiluminescent reaction
956 was visualised using the ImageQuant LAS 4000 imager. After OxyS detection, the
957 membrane was stripped and re-probed with the DIG-anti-5S probe to detect the 5S
958 ribosomal RNA, used as a loading control. The ssRNA DIG-labelled probes DIG-anti-OxyS
959 and DIG-anti-5S were synthesised with the T7 polymerase and DNA templates obtained
960 by PCR with template 4/74 gDNA and primer pairs NW_485/NW_485 and DH58/DH59,
961 respectively.

962

963 **Quantification and statistical analysis**

964

965 Numerical data were plotted and analysed using Microsoft Excel (version 16.46). Data are
966 presented as the mean of three to six biological replicates \pm standard deviation, as
967 indicated in the figures. The unpaired *t*-test was used to compare the groups and statistical
968 significance is indicated on the figures. *P* values (two-tail) are reported using the following
969 criteria: 0.0001 to 0.001 = ***, 0.001 to 0.01 = **, 0.01 to 0.05 = *, \geq 0.05 = NS

970

971 **Funding**

972

973 This research was funded by a Wellcome Trust Senior Investigator award to JCDH [Grant
974 number 106914/Z/15/Z]. For the purpose of open access, the author has applied a CC BY
975 public copyright licence to any Author Accepted Manuscript version arising from this
976 submission. NW was supported by an Early Postdoc Mobility fellowship from the Swiss
977 National Science Foundation (Project reference P2LAP3_158684).

978

979 **Conflict of interest**

980

981 The authors declare no conflict of interest.

982

983 **Acknowledgements**

984

985 We are very grateful to Aoife Colgan for the construction of several mutants, to Stefano
986 Marzi and Laurent Aussel for helpful advice, and to Paul Loughnane for his expert
987 technical assistance. We also thank Celeste Peterson and Susan Gottesman for sharing
988 preliminary data about the *rbs*-driven regulation of RpoS. Finally, we thank all the present
989 and former members of the Hinton Lab for helpful and productive discussions (in the AJ
990 and elsewhere).

991

992 **References**

- 993 1. Rohmer L, Hocquet D, Miller SI. Are pathogenic bacteria just looking for food?
994 Metabolism and microbial pathogenesis. *Trends Microbiol.* 2011;19: 341–348.
995 doi:10.1016/j.tim.2011.04.003
- 996 2. Schubert C, Uden G. C₄-dicarboxylates as growth substrates and signaling
997 molecules for commensal and pathogenic enteric bacteria in mammalian intestine. *J*
998 *Bacteriol.* 2022;Jan 3. doi:10.1128/JB.00545-21
- 999 3. De Vadder F, Kovatcheva-Datchary P, Zitoun C, Duchamp A, Bäckhed F, Mithieux
1000 G. Microbiota-Produced Succinate Improves Glucose Homeostasis via Intestinal
1001 Gluconeogenesis. *Cell Metab.* 2016;24: 151–157.
1002 doi:<https://doi.org/10.1016/j.cmet.2016.06.013>
- 1003 4. Petersen E, Miller SI. The cellular microbiology of *Salmonellae* interactions with
1004 macrophages. *Cell Microbiol.* 2019;21. doi:10.1111/cmi.13116
- 1005 5. Spiga L, Winter MG, Furtado de Carvalho T, Zhu W, Hughes ER, Gillis CC, et al. An
1006 Oxidative Central Metabolism Enables *Salmonella* to Utilize Microbiota-Derived
1007 Succinate. *Cell Host Microbe.* 2017. doi:10.1016/j.chom.2017.07.018
- 1008 6. Haraga A, Ohlson MB, Miller SI. *Salmonellae* interplay with host cells. *Nat Rev*
1009 *Microbiol.* 2008;6: 53–66. doi:10.1038/nrmicro1788
- 1010 7. Fàbrega A, Vila J. *Salmonella enterica* Serovar Typhimurium Skills To Succeed in
1011 the Host: Virulence and Regulation. *Clin Microbiol Rev.* 2013;26: 308–341.
1012 doi:10.1128/CMR.00066-12
- 1013 8. Murphy MP, O’Neill LAJ. Krebs Cycle Reimagined: The Emerging Roles of
1014 Succinate and Itaconate as Signal Transducers. *Cell.* 2018.
1015 doi:10.1016/j.cell.2018.07.030
- 1016 9. Mills E, O’Neill LAJ. Succinate: A metabolic signal in inflammation. *Trends in Cell*
1017 *Biology.* 2014. doi:10.1016/j.tcb.2013.11.008
- 1018 10. Ryan DG, O’Neill LAJ. Krebs Cycle Reborn in Macrophage Immunometabolism.
1019 *Annual Review of Immunology.* 2020. doi:10.1146/annurev-immunol-081619-104850
- 1020 11. Jiang L, Wang P, Song X, Zhang H, Ma S, Wang J, et al. *Salmonella* Typhimurium
1021 reprograms macrophage metabolism via T3SS effector SopE2 to promote
1022 intracellular replication and virulence. *Nat Commun.* 2021;12: 879.
1023 doi:10.1038/s41467-021-21186-4
- 1024 12. Bowden SD, Rowley G, Hinton JCD, Thompson A. Glucose and Glycolysis Are
1025 Required for the Successful Infection of Macrophages and Mice by *Salmonella*
1026 *enterica* Serovar Typhimurium. *Infect Immun.* 2009;77: 3117–3126.

- 1027 doi:10.1128/IAI.00093-09
- 1028 13. Rosenberg G, Yehezkel D, Hoffman D, Ciolli Mattioli C, Fremder M, Ben-Arosh H, et
1029 al. Host succinate is an activation signal for *Salmonella* virulence during intracellular
1030 infection. *Science* (80-). 2021. doi:10.1126/science.aba8026
- 1031 14. Bowden SD, Ramachandran VK, Knudsen GM, Hinton JCD, Thompson A. An
1032 Incomplete TCA Cycle Increases Survival of *Salmonella* Typhimurium during
1033 Infection of Resting and Activated Murine Macrophages. *PLoS One*. 2010.
1034 doi:10.1371/journal.pone.0013871
- 1035 15. Hensel M, Shea JE, Waterman SR, Mundy R, Nikolaus T, Banks G, et al. Genes
1036 encoding putative effector proteins of the type III secretion system of *Salmonella*
1037 pathogenicity island 2 are required for bacterial virulence and proliferation in
1038 macrophages. *Mol Microbiol*. 1998;30: 163–174.
- 1039 16. Hersch SJ, Radan B, Ilyas B, Lavoie P, Navarre WW. A stress-induced block in
1040 dicarboxylate uptake and utilization in *Salmonella*. *J Bacteriol*. 2021; JB.00487-20.
1041 doi:10.1128/JB.00487-20
- 1042 17. Cecchini G, Schröder I, Gunsalus RP, Maklashina E. Succinate dehydrogenase and
1043 fumarate reductase from *Escherichia coli*. *Biochim Biophys Acta - Bioenerg*.
1044 2002;1553: 140–157. doi:[https://doi.org/10.1016/S0005-2728\(01\)00238-9](https://doi.org/10.1016/S0005-2728(01)00238-9)
- 1045 18. Surmann K, Stopp M, Wörner S, Dhople VM, Völker U, Uden G, et al. Fumarate
1046 dependent protein composition under aerobic and anaerobic growth conditions in
1047 *Escherichia coli*. *J Proteomics*. 2020;212: 103583. doi:10.1016/j.jprot.2019.103583
- 1048 19. Fang FC, Libby SJ, Buchmeier NA, Loewen PC, Switala J, Harwood J, et al. The
1049 alternative σ factor KatF (RpoS) regulates *Salmonella* virulence. *Proc Natl Acad Sci*
1050 *U S A*. 1992. doi:10.1073/pnas.89.24.11978
- 1051 20. Soo Lee I, Lin J, Hall HK, Bearson B, Foster JW. The stationary-phase sigma factor
1052 σ^S (RpoS) is required for a sustained acid tolerance response in virulent *Salmonella*
1053 *typhimurium*. *Mol Microbiol*. 1995;17. doi:10.1111/j.1365-
1054 2958.1995.mmi_17010155.x
- 1055 21. Knudsen GM, Nielsen M-B, Grassby T, Danino-Appleton V, Thomsen LE,
1056 Colquhoun IJ, et al. A third mode of surface-associated growth: immobilization of
1057 *Salmonella enterica* serovar Typhimurium modulates the RpoS-directed
1058 transcriptional programme. *Environ Microbiol*. 2012;14: 1855–1875.
- 1059 22. Lago M, Monteil V, Douche T, Guglielmini J, Criscuolo A, Maufrais C, et al.
1060 Proteome remodelling by the stress sigma factor RpoS/ σ^S in *Salmonella*:
1061 Identification of small proteins and evidence for post-transcriptional regulation. *Sci*

- 1062 Rep. 2017. doi:10.1038/s41598-017-02362-3
- 1063 23. Robbe-Saule V, Lopes MD, Kolb A, Norel F. Physiological effects of *crl* in
1064 *Salmonella* are modulated by σ^S level and promoter specificity. J Bacteriol. 2007.
1065 doi:10.1128/JB.01919-06
- 1066 24. Lévi-Meyrueis C, Monteil V, Sismeiro O, Dillies MA, Monot M, Jagla B, et al.
1067 Expanding the RpoS/ σ^S -network by RNA sequencing and identification of σ^S -
1068 controlled small RNAs in *Salmonella*. PLoS One. 2014.
1069 doi:10.1371/journal.pone.0096918
- 1070 25. Lévi-Meyrueis C, Monteil V, Sismeiro O, Dillies MA, Kolb A, Monot M, et al.
1071 Repressor activity of the RpoS/ σ^S -dependent RNA polymerase requires DNA
1072 binding. Nucleic Acids Res. 2015. doi:10.1093/nar/gku1379
- 1073 26. Uden G, Strecker A, Kleefeld A, Kim O Bin. C₄-Dicarboxylate Utilization in Aerobic
1074 and Anaerobic Growth. EcoSal Plus. 2016. doi:10.1128/ecosalplus.esp-0021-2015
- 1075 27. Robbe-Saule V, Algorta G, Rouilhac I, Norel F. Characterization of the RpoS status
1076 of clinical isolates of *Salmonella enterica*. Appl Environ Microbiol. 2003.
1077 doi:10.1128/AEM.69.8.4352-4358.2003
- 1078 28. Dong T, Schellhorn HE. Control of RpoS in global gene expression of *Escherichia*
1079 *coli* in minimal media. Mol Genet Genomics. 2009. doi:10.1007/s00438-008-0389-3
- 1080 29. Chiang SM, Dong T, Edge TA, Schellhorn HE. Phenotypic diversity caused by
1081 differential RpoS activity among environmental *Escherichia coli* isolates. Appl
1082 Environ Microbiol. 2011. doi:10.1128/AEM.05274-11
- 1083 30. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, et al.
1084 Epidemic multiple drug resistant *Salmonella* Typhimurium causing invasive disease
1085 in sub-Saharan Africa have a distinct genotype. Genome Res. 2009.
1086 doi:10.1101/gr.091017.109
- 1087 31. Feasey NA, Hadfield J, Keddy KH, Dallman TJ, Jacobs J, Deng X, et al. Distinct
1088 *Salmonella* Enteritidis lineages associated with enterocolitis in high-income settings
1089 and invasive disease in low-income settings. Nat Genet. 2016. doi:10.1038/ng.3644
- 1090 32. Perez-Sepulveda BM, Predeus A V, Fong WY, Parry CM, Cheesbrough J, Wigley P,
1091 et al. Complete Genome Sequences of African *Salmonella enterica* Serovar
1092 Enteritidis Clinical Isolates Associated with Bloodstream Infection. Bruno V, editor.
1093 Microbiol Resour Announc. 2021;10. doi:10.1128/MRA.01452-20
- 1094 33. Pulford C V., Wenner N, Redway ML, Rodwell E V., Webster HJ, Escudero R, et al.
1095 The diversity, evolution and ecology of *Salmonella* in venomous snakes. PLoS Negl
1096 Trop Dis. 2019. doi:10.1371/journal.pntd.0007169

- 1097 34. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricija
1098 L, et al. Genome sequencing reveals diversification of virulence factor content and
1099 possible host adaptation in distinct subpopulations of *Salmonella enterica*. BMC
1100 Genomics. 2011. doi:10.1186/1471-2164-12-245
- 1101 35. Richardson EJ, Limaye B, Inamdar H, Datta A, Manjari KS, Pullinger GD, et al.
1102 Genome sequences of *Salmonella enterica* serovar Typhimurium, Choleraesuis,
1103 Dublin, and Gallinarum strains of well-defined virulence in food-producing animals.
1104 Journal of Bacteriology. 2011. doi:10.1128/JB.00394-11
- 1105 36. Bialek-Davenet S, Criscuolo A, Ailloud F, Passet V, Jones L, Delannoy-Vieillard AS,
1106 et al. Genomic definition of hypervirulent and multidrug-resistant *klebsiella*
1107 *pneumoniae* clonal groups. Emerg Infect Dis. 2014. doi:10.3201/eid2011.140206
- 1108 37. Schauer DB, Zabel BA, Pedraza IF, O'Hara CM, Steigerwalt AG, Brenner DJ.
1109 Genetic and biochemical characterization of *Citrobacter rodentium* sp. nov. J Clin
1110 Microbiol. 1995. doi:10.1128/jcm.33.8.2064-2068.1995
- 1111 38. Van Der Woude MW, Bäumlner AJ. Phase and antigenic variation in bacteria. Clinical
1112 Microbiology Reviews. 2004. doi:10.1128/CMR.17.3.581-611.2004
- 1113 39. Sánchez-Romero MA, Casadesús J. The bacterial epigenome. Nature Reviews
1114 Microbiology. 2020. doi:10.1038/s41579-019-0286-2
- 1115 40. Kröger C, Dillon SC, Cameron ADS, Papenfort K, Sivasankaran SK, Hokamp K, et
1116 al. The transcriptional landscape and small RNAs of *Salmonella enterica* serovar
1117 Typhimurium. Proc Natl Acad Sci U S A. 2012. doi:10.1073/pnas.1201061109
- 1118 41. Colgan AM, Kröger C, Diard M, Hardt WD, Puente JL, Sivasankaran SK, et al. The
1119 Impact of 18 Ancestral and Horizontally-Acquired Regulatory Proteins upon the
1120 Transcriptome and sRNA Landscape of *Salmonella enterica* serovar Typhimurium.
1121 PLoS Genet. 2016. doi:10.1371/journal.pgen.1006258
- 1122 42. Kutsukake K, Ikebe T, Yamamoto S. Two novel regulatory genes, *fliT* and *fliZ*, in the
1123 flagellar regulon of *Salmonella*. Genes Genet Syst. 1999. doi:10.1266/ggs.74.287
- 1124 43. De Bruijn FJ, Lupski JR. The use of transposon Tn5 mutagenesis in the rapid
1125 generation of correlated physical and genetic maps of DNA segments cloned into
1126 multicopy plasmids—a review. Gene. 1984;27: 131–149.
- 1127 44. Janausch IG, Zientz E, Tran QH, Kröger A, Uden G. C₄-dicarboxylate carriers and
1128 sensors in bacteria. Biochimica et Biophysica Acta - Bioenergetics. 2002.
1129 doi:10.1016/S0005-2728(01)00233-X
- 1130 45. Santiago-Frangos A, Woodson SA. Hfq chaperone brings speed dating to bacterial
1131 sRNA. Wiley Interdiscip Rev RNA. 2018. doi:10.1002/wrna.1475

- 1132 46. Vogel J, Luisi BF. Hfq and its constellation of RNA. *Nature Reviews Microbiology*.
1133 2011. doi:10.1038/nrmicro2615
- 1134 47. Massé E, Escorcía FE, Gottesman S. Coupled degradation of a small regulatory
1135 RNA and its mRNA targets in *Escherichia coli*. *Genes Dev*. 2003.
1136 doi:10.1101/gad.1127103
- 1137 48. Desnoyers G, Massé E. Noncanonical repression of translation initiation through
1138 small RNA recruitment of the RNA chaperone Hfq. *Genes Dev*. 2012.
1139 doi:10.1101/gad.182493.111
- 1140 49. Massé E, Gottesman S. A small RNA regulates the expression of genes involved in
1141 iron metabolism in *Escherichia coli*. *Proc Natl Acad Sci U S A*. 2002.
1142 doi:10.1073/pnas.032066599
- 1143 50. Kim JN, Kwon YM. Genetic and phenotypic characterization of the RyhB regulon in
1144 *Salmonella Typhimurium*. *Microbiol Res*. 2013. doi:10.1016/j.micres.2012.06.007
- 1145 51. Battesti A, Majdalani N, Gottesman S. The RpoS-Mediated General Stress
1146 Response in *Escherichia coli*. *Annu Rev Microbiol*. 2011. doi:10.1146/annurev-
1147 micro-090110-102946
- 1148 52. Soper T, Mandin P, Majdalani N, Gottesman S, Woodson SA. Positive regulation by
1149 small RNAs and the role of Hfq. *Proc Natl Acad Sci U S A*. 2010.
1150 doi:10.1073/pnas.1004435107
- 1151 53. Sedlyarova N, Shamovsky I, Bharati BK, Epshtein V, Chen J, Gottesman S, et al.
1152 sRNA-Mediated Control of Transcription Termination in *E. coli*. *Cell*. 2016.
1153 doi:10.1016/j.cell.2016.09.004
- 1154 54. De Lay N, Gottesman S. Role of polynucleotide phosphorylase in sRNA function in
1155 *Escherichia coli*. *RNA*. 2011. doi:10.1261/rna.2531211
- 1156 55. Storz G. New perspectives: Insights into oxidative stress from bacterial studies. *Arch*
1157 *Biochem Biophys*. 2016. doi:10.1016/j.abb.2015.11.022
- 1158 56. Zheng M, Åslund F, Storz G. Activation of the OxyR transcription factor by reversible
1159 disulfide bond formation. *Science (80-)*. 1998. doi:10.1126/science.279.5357.1718
- 1160 57. Storz G, Tartaglia LA, Ames BN. The OxyR regulon. *Antonie Van Leeuwenhoek*.
1161 1990. doi:10.1007/BF00548927
- 1162 58. Chiang SM, Schellhorn HE. Regulators of oxidative stress response genes in
1163 *Escherichia coli* and their functional conservation in bacteria. *Archives of*
1164 *Biochemistry and Biophysics*. 2012. doi:10.1016/j.abb.2012.02.007
- 1165 59. Altuvia S, Weinstein-Fischer D, Zhang A, Postow L, Storz G. A small, stable RNA
1166 induced by oxidative stress: Role as a pleiotropic regulator and antimutator. *Cell*.

- 1167 1997. doi:10.1016/S0092-8674(00)80312-8
- 1168 60. Zhang A, Altuvia S, Tiwari A, Argaman L, Hengge-Aronis R, Storz G. The OxyS
1169 regulatory RNA represses *rpoS* translation and binds the Hfq (HF-I) protein. EMBO
1170 J. 1998. doi:10.1093/emboj/17.20.6061
- 1171 61. Zhang A, Wassarman KM, Ortega J, Steven AC, Storz G. The Sm-like Hfq protein
1172 increases OxyS RNA interaction with target mRNAs. Mol Cell. 2002.
1173 doi:10.1016/S1097-2765(01)00437-3
- 1174 62. Christman MF, Morgan RW, Jacobson FS, Ames BN. Positive control of a regulon
1175 for defenses against oxidative stress and some heat-shock proteins in *Salmonella*
1176 *typhimurium*. Cell. 1985. doi:10.1016/S0092-8674(85)80056-8
- 1177 63. Christman MF, Storz G, Ames BN. OxyR, a positive regulator of hydrogen peroxide-
1178 inducible genes in *Escherichia coli* and *Salmonella typhimurium*, is homologous to a
1179 family of bacterial regulatory proteins. Proc Natl Acad Sci U S A. 1989.
1180 doi:10.1073/pnas.86.10.3484
- 1181 64. Kullik I, Toledano MB, Tartaglia LA, Storz G. Mutational analysis of the redox-
1182 sensitive transcriptional regulator OxyR: Regions important for oxidation and
1183 transcriptional activation. J Bacteriol. 1995. doi:10.1128/jb.177.5.1275-1284.1995
- 1184 65. Tjaden B, Goodwin SS, Opdyke JA, Guillier M, Fu DX, Gottesman S, et al. Target
1185 prediction for small, noncoding RNAs in bacteria. Nucleic Acids Res. 2006.
1186 doi:10.1093/nar/gkl356
- 1187 66. Hemm MR, Paul BJ, Miranda-Ríos J, Zhang A, Soltanzad N, Storz G. Small stress
1188 response proteins in *Escherichia coli*: Proteins missed by classical proteomic
1189 studies. J Bacteriol. 2010. doi:10.1128/JB.00872-09
- 1190 67. Sittka A, Pfeiffer V, Tedin K, Vogel J. The RNA chaperone Hfq is essential for the
1191 virulence of *Salmonella typhimurium*. Mol Microbiol. 2007. doi:10.1111/j.1365-
1192 2958.2006.05489.x
- 1193 68. Phadtare S, Inouye M. Role of CspC and CspE in regulation of expression of RpoS
1194 and UspA, the stress response proteins in *Escherichia coli*. J Bacteriol. 2001.
1195 doi:10.1128/JB.183.4.1205-1214.2001
- 1196 69. Cohen-Or I, Shenhar Y, Biran D, Ron EZ. CspC regulates *rpoS* transcript levels and
1197 complements *hfq* deletions. Res Microbiol. 2010. doi:10.1016/j.resmic.2010.06.009
- 1198 70. Michaux C, Holmqvist E, Vasicek E, Sharan M, Barquist L, Westermann AJ, et al.
1199 RNA target profiles direct the discovery of virulence functions for the cold-shock
1200 proteins CspC and CspE. Proc Natl Acad Sci U S A. 2017.
1201 doi:10.1073/pnas.1620772114

- 1202 71. Keto-Timonen R, Hietala N, Palonen E, Hakakorpi A, Lindström M, Korkeala H. Cold
1203 Shock Proteins: A Minireview with Special Emphasis on Csp-family of
1204 Enteropathogenic *Yersinia*. *Front Microbiol.* 2016. doi:10.3389/fmicb.2016.01151
- 1205 72. Steinmetz PA, Wörner S, Uden G. Differentiation of DctA and DcuS function in the
1206 DctA/DcuS sensor complex of *Escherichia coli*: Function of DctA as an activity
1207 switch and of DcuS as the C₄-dicarboxylate sensor. *Mol Microbiol.* 2014.
1208 doi:10.1111/mmi.12759
- 1209 73. Davies SJ, Golby P, Omrani D, Broad SA, Harrington VL, Guest JR, et al.
1210 Inactivation and regulation of the aerobic C₄-dicarboxylate transport (*dctA*) gene of
1211 *Escherichia coli*. *sc.* 1999. doi:10.1128/jb.181.18.5624-5635.1999
- 1212 74. Amin MR, Korchinski L, Yoneda JK, Thakkar R, Sanson CLA, Fitzgerald SF, et al. A
1213 mutation in the putative CRP binding site of the *dctA* promoter of *Salmonella*
1214 *enterica* serovar Typhimurium enables growth with low orotate concentrations. *Can J*
1215 *Microbiol.* 2022.
- 1216 75. Zientz E, Bongaerts J, Uden G. Fumarate regulation of gene expression in
1217 *Escherichia coli* by the DcuSR (*dcuSR* genes) two-component regulatory system. *J*
1218 *Bacteriol.* 1998. doi:10.1128/jb.180.20.5421-5425.1998
- 1219 76. Giel JL, Rodionov D, Liu M, Blattner FR, Kiley PJ. IscR-dependent gene expression
1220 links iron-sulphur cluster assembly to the control of O₂-regulated genes in
1221 *Escherichia coli*. *Mol Microbiol.* 2006. doi:10.1111/j.1365-2958.2006.05160.x
- 1222 77. Py B, Barras F. Building Feg-S proteins: Bacterial strategies. *Nature Reviews*
1223 *Microbiology.* 2010. doi:10.1038/nrmicro2356
- 1224 78. Schwartz CJ, Giel JL, Patschkowski T, Luther C, Ruzicka FJ, Beinert H, et al. IscR,
1225 an Fe-S cluster-containing transcription factor, represses expression of *Escherichia*
1226 *coli* genes encoding Fe-S cluster assembly proteins. *Proc Natl Acad Sci U S A.*
1227 2001. doi:10.1073/pnas.251550898
- 1228 79. Yeo WS, Lee JH, Lee KC, Roe JH. IscR acts as an activator in response to oxidative
1229 stress for the *suf* operon encoding Fe-S assembly proteins. *Mol Microbiol.* 2006.
1230 doi:10.1111/j.1365-2958.2006.05220.x
- 1231 80. Nesbit AD, Giel JL, Rose JC, Kiley PJ. Sequence-Specific Binding to a Subset of
1232 IscR-Regulated Promoters Does Not Require IscR Fe-S Cluster Ligation. *J Mol Biol.*
1233 2009. doi:10.1016/j.jmb.2009.01.055
- 1234 81. Quandt EM, Deatherage DE, Ellington AD, Georgiou G, Barrick JE. Recursive
1235 genomewide recombination and sequencing reveals a key refinement step in the
1236 evolution of a metabolic innovation in *Escherichia coli*. *Proc Natl Acad Sci U S A.*

- 1237 2014. doi:10.1073/pnas.1314561111
- 1238 82. Vergnes A, Viala JPM, Ouadah-Tsabet R, Pocachard B, Loiseau L, Méresse S, et al.
1239 The iron–sulfur cluster sensor IscR is a negative regulator of Spi1 type III secretion
1240 system in *Salmonella enterica*. Cell Microbiol. 2017. doi:10.1111/cmi.12680
- 1241 83. Rajagopalan S, Teter SJ, Zwart PH, Brennan RG, Phillips KJ, Kiley PJ. Studies of
1242 IscR reveal a unique mechanism for metal-dependent regulation of DNA binding
1243 specificity. Nat Struct Mol Biol. 2013. doi:10.1038/nsmb.2568
- 1244 84. Zwir I, Latifi T, Perez JC, Huang H, Groisman EA. The promoter architectural
1245 landscape of the *Salmonella* PhoP regulon. Mol Microbiol. 2012. doi:10.1111/j.1365-
1246 2958.2012.08036.x
- 1247 85. Bougdour A, Wickner S, Gottesman S. Modulating RssB activity: IraP, a novel
1248 regulator of σ^S stability in *Escherichia coli*. Genes Dev. 2006.
1249 doi:10.1101/gad.1400306
- 1250 86. Bougdour A, Cuning C, Baptiste PJ, Elliott T, Gottesman S. Multiple pathways for
1251 regulation of σ^S (RpoS) stability in *Escherichia coli* via the action of multiple anti-
1252 adaptors. Mol Microbiol. 2008. doi:10.1111/j.1365-2958.2008.06146.x
- 1253 87. Robbe-Saule V, Jaumouillé V, Prévost MC, Guadagnini S, Talhouarne C, Mathout
1254 H, et al. Crl activates transcription initiation of RpoS-regulated genes involved in the
1255 multicellular behavior of *Salmonella enterica* serovar Typhimurium. J Bacteriol.
1256 2006. doi:10.1128/JB.00033-06
- 1257 88. Mauzy CA, Hermodson MA. Structural and functional analyses of the repressor,
1258 RbsR, of the ribose operon of *Escherichia coli*. Protein Sci. 1992.
1259 doi:10.1002/pro.5560010701
- 1260 89. Peterson C, Dorlean S, Parsons D, Tran T, Dey A. Regulation of RpoS by RbsD in
1261 *Escherichia coli*. FASEB J. 2019;33: 713–778.
- 1262 90. Auvray F, Thomas J, Fraser GM, Hughes C. Flagellin polymerisation control by a
1263 cytosolic export chaperone. J Mol Biol. 2001. doi:10.1006/jmbi.2001.4597
- 1264 91. Bennett JCQ, Thomas J, Fraser GM, Hughes C. Substrate complexes and domain
1265 organization of the *Salmonella* flagellar export chaperones FlgN and FliT. Mol
1266 Microbiol. 2001. doi:10.1046/j.1365-2958.2001.02268.x
- 1267 92. Lehner AF, Harvey S, Hill CW. Mapping and spacer identification of rRNA operons
1268 of *Salmonella typhimurium*. J Bacteriol. 1984. doi:10.1128/jb.160.2.682-686.1984
- 1269 93. Laursen BS, Sørensen HP, Mortensen KK, Sperling-Petersen HU. Initiation of
1270 Protein Synthesis in Bacteria. Microbiol Mol Biol Rev. 2005.
1271 doi:10.1128/mnbr.69.1.101-123.2005

- 1272 94. Gualerzi CO, Pon CL. Initiation of mRNA translation in bacteria: Structural and
1273 dynamic aspects. *Cellular and Molecular Life Sciences*. 2015. doi:10.1007/s00018-
1274 015-2010-3
- 1275 95. Shine J, Dalgarno L. The 3' terminal sequence of *Escherichia coli* 16S ribosomal
1276 RNA: complementarity to nonsense triplets and ribosome binding sites. *Proc Natl*
1277 *Acad Sci U S A*. 1974. doi:10.1073/pnas.71.4.1342
- 1278 96. Steitz JA, Jakes K. How ribosomes select initiator regions in mRNA: base pair
1279 formation between the 3' terminus of 16S rRNA and the mRNA during initiation of
1280 protein synthesis in *Escherichia coli*. *Proc Natl Acad Sci U S A*. 1975.
1281 doi:10.1073/pnas.72.12.4734
- 1282 97. Kurylo CM, Parks MM, Juetter MF, Zinshteyn B, Altman RB, Thibado JK, et al.
1283 Endogenous rRNA Sequence Variation Can Regulate Stress Response Gene
1284 Expression and Phenotype. *Cell Rep*. 2018. doi:10.1016/j.celrep.2018.08.093
- 1285 98. Saito K, Green R, Buskirk AR. Translational initiation in *E. coli* occurs at the correct
1286 sites genome-wide in the absence of mRNA-rRNA base-pairing. *Elife*. 2020.
1287 doi:10.7554/eLife.55002
- 1288 99. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance.
1289 *Nature Reviews Microbiology*. 2014. doi:10.1038/nrmicro3155
- 1290 100. Hobbs JK, Boraston AB. (p)ppGpp and the Stringent Response: An Emerging Threat
1291 to Antibiotic Therapy. *ACS Infect Dis*. 2019. doi:10.1021/acsinfecdis.9b00204
- 1292 101. Kudrin P, Varik V, Oliveira SRA, Beljantseva J, Del Peso Santos T, Dzhygyr I, et al.
1293 Subinhibitory concentrations of bacteriostatic antibiotics induce relA-dependent and
1294 relA-independent tolerance to β -lactams. *Antimicrob Agents Chemother*. 2017.
1295 doi:10.1128/AAC.02173-16
- 1296 102. Ude S, Lassak J, Starosta AL, Kraxenberger T, Wilson DN, Jung K. Translation
1297 elongation factor EF-P alleviates ribosome stalling at polyproline stretches. *Science*
1298 (80-). 2013. doi:10.1126/science.1228985
- 1299 103. Starosta AL, Lassak J, Jung K, Wilson DN. The bacterial translation stress
1300 response. *FEMS Microbiology Reviews*. 2014. doi:10.1111/1574-6976.12083
- 1301 104. Schellhorn HE. Function, Evolution, and Composition of the RpoS Regulon in
1302 *Escherichia coli*. *Frontiers in Microbiology*. 2020. doi:10.3389/fmicb.2020.560099
- 1303 105. Ferenci T, Spira B. Variation in stress responses within a bacterial species and the
1304 indirect costs of stress resistance. *Annals of the New York Academy of Sciences*.
1305 2007. doi:10.1196/annals.1391.003
- 1306 106. Faber F, Bäumlér AJ. The impact of intestinal inflammation on the nutritional

- 1307 environment of the gut microbiota. *Immunology Letters*. 2014.
1308 doi:10.1016/j.imlet.2014.04.014
- 1309 107. Bäumlér AJ, Sperandio V. Interactions between the microbiota and pathogenic
1310 bacteria in the gut. *Nature*. 2016;535: 85–93. doi:10.1038/nature18849
- 1311 108. Srikumar S, Kröger C, Hébrard M, Colgan A, Owen S V., Sivasankaran SK, et al.
1312 RNA-seq Brings New Insights to the Intra-Macrophage Transcriptome of *Salmonella*
1313 Typhimurium. *PLoS Pathog*. 2015. doi:10.1371/journal.ppat.1005262
- 1314 109. Chen CY, Eckmann L, Libby SJ, Fang FC, Okamoto S, Kagnoff MF, et al.
1315 Expression of *Salmonella typhimurium rpoS* and *rpoS*-dependent genes in the
1316 intracellular environment of eukaryotic cells. *Infect Immun*. 1996;64: 4739–4743.
1317 doi:10.1128/iai.64.11.4739-4743.1996
- 1318 110. Herzberg M, Jawad MJ, Pratt D. Succinate metabolism and virulence in *salmonella*
1319 *typhimurium*. *Nature*. 1964. doi:10.1038/2041285b0
- 1320 111. Herzberg M, Jawad MJ, PRATT D. Correlation of Succinate Metabolism and
1321 Virulence in *Salmonella typhimurium*. *J Bacteriol*. 1965. doi:10.1128/jb.89.1.185-
1322 192.1965
- 1323 112. Wray C, Sojka WJ. Experimental *Salmonella* Typhimurium infection in calves. *Res*
1324 *Vet Sci*. 1978. doi:10.1016/s0034-5288(18)32968-0
- 1325 113. Simon R, Priefer U, Pühler A. A broad host range mobilization system for *in vivo*
1326 genetic engineering: Transposon mutagenesis in gram negative bacteria.
1327 *Bio/Technology*. 1983. doi:10.1038/nbt1183-784
- 1328 114. Sambrook J, Russell DW. *Molecular Cloning: A Laboratory Manual, Third Edition*.
1329 *Molecular Cloning: a laboratory a manual*,. 2001.
- 1330 115. Martínez-García E, de Lorenzo V. Engineering multiple genomic deletions in Gram-
1331 negative bacteria: Analysis of the multi-resistant antibiotic profile of *Pseudomonas*
1332 *putida* KT2440. *Environ Microbiol*. 2011. doi:10.1111/j.1462-2920.2011.02538.x
- 1333 116. Green R, Rogers EJ. Chemical Transformation of *E. coli*. *Methods Enzym*. 2014;
1334 329–336. doi:10.1016/B978-0-12-418687-3.00028-8
- 1335 117. Owen S V., Wenner N, Dulberger CL, Rodwell E V., Bowers-Barnard A, Quinones-
1336 Olvera N, et al. Prophages encode phage-defense systems with cognate self-
1337 immunity. *Cell Host Microbe*. 2021;29. doi:10.1016/j.chom.2021.09.002
- 1338 118. Edwards RA, Allen Helm R, Maloy SR. Increasing DNA transfer efficiency by
1339 temporary inactivation of host restriction. *Biotechniques*. 1999.
1340 doi:10.2144/99265st02
- 1341 119. Larsen RA, Wilson MM, Guss AM, Metcalf WW. Genetic analysis of pigment

- 1342 biosynthesis in *Xanthobacter autotrophicus* Py2 using a new, highly efficient
1343 transposon mutagenesis system that is functional in a wide variety of bacteria. Arch
1344 Microbiol. 2002. doi:10.1007/s00203-002-0442-2
- 1345 120. Van Den Ent F, Löwe J. RF cloning: A restriction-free method for inserting target
1346 genes into plasmids. J Biochem Biophys Methods. 2006.
1347 doi:10.1016/j.jbbm.2005.12.008
- 1348 121. Corcoran CP, Podkaminski D, Papenfort K, Urban JH, Hinton JCD, Vogel J.
1349 Superfolder GFP reporters validate diverse new mRNA targets of the classic porin
1350 regulator, MicF RNA. Mol Microbiol. 2012. doi:10.1111/j.1365-2958.2012.08031.x
- 1351 122. Heckman KL, Pease LR. Gene splicing and mutagenesis by PCR-driven overlap
1352 extension. Nat Protoc. 2007. doi:10.1038/nprot.2007.132
- 1353 123. Lutz R, Bujard H. Independent and tight regulation of transcriptional units in
1354 *Escherichia coli* via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements.
1355 Nucleic Acids Res. 1997;25: 1203–1210. doi:10.1093/nar/25.6.1203
- 1356 124. Owen S V., Canals R, Wenner N, Hammarlöf D, Kröger C, Hinton J. A window into
1357 lysogeny: Revealing temperate phage biology with transcriptomics. Microb
1358 Genomics. 2020. doi:10.1101/787010
- 1359 125. Hemsley A, Arnheim N, Toney MD, Cortopassi G, Galas DJ. A simple method for
1360 site-directed mutagenesis using the polymerase chain reaction. Nucleic Acids Res.
1361 1989;17: 6545–6551. doi:10.1093/nar/17.16.6545
- 1362 126. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in
1363 *Escherichia coli* K-12 using PCR products. Proc Natl Acad Sci U S A. 2000.
1364 doi:10.1073/pnas.120163297
- 1365 127. Koskiniemi S, Pránting M, Gullberg E, Näsvall J, Andersson DI. Activation of cryptic
1366 aminoglycoside resistance in *Salmonella enterica*. Mol Microbiol. 2011.
1367 doi:10.1111/j.1365-2958.2011.07657.x
- 1368 128. Hammarlöf DL, Kröger C, Owen S V., Canals R, Lacharme-Lora L, Wenner N, et al.
1369 Role of a single noncoding nucleotide in the evolution of an epidemic African clade
1370 of *Salmonella*. Proc Natl Acad Sci U S A. 2018. doi:10.1073/pnas.1714718115
- 1371 129. Owen S V., Wenner N, Canals R, Makumi A, Hammarlöf DL, Gordon MA, et al.
1372 Characterization of the prophage repertoire of African *Salmonella* Typhimurium
1373 ST313 reveals high levels of spontaneous induction of novel phage BTP1. Front
1374 Microbiol. 2017. doi:10.3389/fmicb.2017.00235
- 1375 130. Schmieger H. Phage P22-mutants with increased or decreased transduction
1376 abilities. MGG Mol Gen Genet. 1972. doi:10.1007/BF00270447

- 1377 131. Cherepanov PP, Wackernagel W. Gene disruption in *Escherichia coli*: Tc^R and Km^R
1378 cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance
1379 determinant. *Gene*. 1995. doi:10.1016/0378-1119(95)00193-A
- 1380 132. Schulte M, Sterzenbach T, Miskiewicz K, Elpers L, Hensel M, Hansmeier N. A
1381 versatile remote control system for functional expression of bacterial virulence genes
1382 based on the *tetA* promoter. *Int J Med Microbiol*. 2019.
1383 doi:10.1016/j.ijmm.2018.11.001
- 1384 133. Kröger C, Colgan A, Srikumar S, Händler K, Sivasankaran SK, Hammarlöf DL, et al.
1385 An infection-relevant transcriptomic compendium for *Salmonella enterica* serovar
1386 Typhimurium. *Cell Host Microbe*. 2013. doi:10.1016/j.chom.2013.11.010
- 1387 134. Blank K, Hensel M, Gerlach RG. Rapid and highly efficient method for scarless
1388 mutagenesis within the *Salmonella enterica* chromosome. *PLoS One*. 2011.
1389 doi:10.1371/journal.pone.0015763
- 1390 135. Canals R, Hammarlöf DL, Kröger C, Owen S V., Fong WY, Lacharme-Lora L, et al.
1391 Adding function to the genome of African *Salmonella* Typhimurium ST313 strain
1392 D23580. *PLoS Biol*. 2019. doi:10.1371/journal.pbio.3000059
- 1393 136. Zojer M, Schuster LN, Schulz F, Pfundner A, Horn M, Rattei T. Variant profiling of
1394 evolving prokaryotic populations. *PeerJ*. 2017. doi:10.7717/peerj.2997
- 1395 137. Notley-McRobb L, King T, Ferenci T. *rpoS* mutations and loss of general stress
1396 resistance in *Escherichia coli* populations as a consequence of conflict between
1397 competing stress responses. *J Bacteriol*. 2002. doi:10.1128/JB.184.3.806-811.2002
- 1398 138. Ashton PM, Owen S V., Kaindama L, Rowe WPM, Lane CR, Larkin L, et al. Public
1399 health surveillance in the UK revolutionises our understanding of the invasive
1400 *Salmonella* Typhimurium epidemic in Africa. *Genome Med*. 2017.
1401 doi:10.1186/s13073-017-0480-7
- 1402 139. O'Toole GA, Kolter R. Initiation of biofilm formation in *Pseudomonas fluorescens*
1403 WCS365 proceeds via multiple, convergent signalling pathways: A genetic analysis.
1404 *Mol Microbiol*. 1998. doi:10.1046/j.1365-2958.1998.00797.x
- 1405 140. Bongaerts RJM, Hautefort I, Sidebotham JM, Hinton JCD. Green fluorescent protein
1406 as a marker for conditional gene expression in bacterial cells. *Methods Enzymol*.
1407 2002. doi:10.1016/S0076-6879(02)58080-0
- 1408 141. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction.
1409 *Nucleic Acids Res*. 2003. doi:10.1093/nar/gkg595
- 1410 142. Mann M, Wright PR, Backofen R. IntaRNA 2.0: Enhanced and customizable
1411 prediction of RNA-RNA interactions. *Nucleic Acids Res*. 2017.

- 1412 doi:10.1093/nar/gkx279
- 1413 143. Abo-Amer AE, Munn J, Jackson K, Aktas M, Golby P, Kelly DJ, et al. DNA
1414 Interaction and Phosphotransfer of the C₄-Dicarboxylate-Responsive DcuS-DcuR
1415 Two-Component Regulatory System from *Escherichia coli*. *J Bacteriol.* 2004.
1416 doi:10.1128/JB.186.6.1879-1889.2004
- 1417 144. McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, et al.
1418 Complete genome sequence of *Salmonella enterica* serovar Typhimurium LT2.
1419 *Nature.* 2001. doi:10.1038/35101614
- 1420 145. Bandyra KJ, Sinha D, Syrjanen J, Luisi BF, De Lay NR. The ribonuclease
1421 polynucleotide phosphorylase can interact with small regulatory RNAs in both
1422 protective and degradative modes. *RNA.* 2016. doi:10.1261/rna.052886.115
- 1423 146. Nurmohamed S, Vincent HA, Titman CM, Chandran V, Pears MR, Du D, et al.
1424 Polynucleotide phosphorylase activity may be modulated by metabolites in
1425 *Escherichia coli*. *J Biol Chem.* 2011. doi:10.1074/jbc.M110.200741
- 1426 147. Witan J, Monzel C, Scheu PD, Uden G. The sensor kinase DcuS of *Escherichia*
1427 *coli*: Two stimulus input sites and a merged signal pathway in the DctA/DcuS sensor
1428 unit. *Biological Chemistry.* 2012. doi:10.1515/hsz-2012-0229
- 1429
- 1430


1431 **Table 1: Fifteen mutations that stimulated growth of *S. Typhimurium* upon succinate**

Tn5 mutants		
coordinate	Locus affected and gene product	Tn5 orientation
436621	Insertion in <i>iraP</i> (<i>yaiB</i>), anti-adaptor protein IraP	<
436616	Insertion in <i>iraP</i>	<
2007729	Insertion in <i>fliD</i> , flagellar hook associated protein FliD	>
2007415	Insertion in <i>fliD</i>	>
4118507	Insertion in <i>rbsR</i> , ribose operon repressor RbsR	>
1893137	Insertion in <i>cspC</i> , cold shock-like protein CspC	>
1893511	Insertion in the <i>yobJ-cspC</i> operon 5'-UTR (<i>yobJ-cspC</i> TSS: coordinate 1893683)	>
1893502	Insertion in the <i>yobJ-cspC</i> operon 5'-UTR	<
Spontaneous Succ⁺ mutants		
Mutation name	Locus affected and gene product	Mutation coordinates & characterisation
<i>oxyR^{mut}</i>	<i>oxyR</i> , encoding the regulatory protein sensor for oxidative stress OxyR	Indel, additional CTA (leucine) codon between coordinates 4365235-4365236 in <i>oxyR</i>
<i>iscR^{STOP}</i>	<i>iscR</i> (<i>yfhP</i>), encoding the Fe-S cluster regulator protein IscR	SNP G→A coordinate 2680848, premature stop codon (Q ⁹⁹ →STOP) in <i>IscR</i>
<i>dctA^{mut1}</i>	5'-UTR of <i>dctA</i> , encoding the aerobic C ₄ -dicarboxylate transporter protein DctA	SNP T→C position 3812916 in <i>dctA</i> 5'-UTR (<i>dctA</i> TSS coordinate 3812935)
<i>dctA^{mut2}</i>	5'-UTR of <i>dctA</i> , encoding the aerobic C ₄ -dicarboxylate transporter protein DctA	SNP G→A position 3812910 in <i>dctA</i> 5'-UTR
<i>rbsR^{mut}</i>	12 bp insertion in <i>rbsR</i> , ribose operon repressor RbsR	Indel: in frame insertion of 4 codons (TATCAGGCGCTA→YQAL) between codons 255 and 256 of <i>rbsR</i> , coordinates 4118620-4118621
<i>rrsH^{mut}</i>	<i>rrsH</i> , encoding the 16S ribosomal RNA RrsH	SNP T→A coordinate 290706 in the aSD ^d of <i>rrsH</i> : CCTCCTT→CCACCTT
<i>rrsA^{mut}</i>	<i>rrsA</i> , encoding the 16S ribosomal RNA RrsA	SNP C→A coordinate 4219140 in the aSD ^d of <i>rrsA</i> : CCTCCTT→CATCCTT

1432 Table 1: The mutation coordinates and the annotations correspond to the *S. Typhimurium*
 1433 4/74 reference genome (GenBank: CP002487.1)[35]. For the Tn5 insertions, the
 1434 coordinates of the nucleotide after which the transposon was mapped is indicated.
 1435 Transposon orientation is indicated as follows. >: the Tn5 *aph* gene (Km^R) is encoded on
 1436 the positive DNA strand of the 4/74 chromosome; <: *aph* is encoded on the negative
 1437 strand. When insertions and mutations were mapped within the 5' untranslated regions (5'-
 1438 UTR) of a transcribed gene, the coordinates of upstream transcription start site (TSS) is
 1439 indicated, according to the SalComMac transcriptomic database
 1440 (http://bioinf.gen.tcd.ie/cgi-bin/salcom.pl?db=salcom_mac_HL [108,133]. "IGR" denotes

1441 intergenic regions, “SNP” single nucleotide polymorphisms, “Indel” insertions & deletion
1442 and “aSD” denotes the anti-Shine-Dalgarno (CCTCCTT) sequence of the 16S rRNAs.
1443

1444 **Main figures**



1445

1446 **Figure 1: Inhibition of growth of most *Salmonella* serovars and *K. pneumoniae* on**

1447 **succinate minimal medium.** The indicated strains of *E. coli*, *Salmonella*, *Citrobacter* and

1448 *Klebsiella* were spread on M9+Succ agar plates and incubated at 37°C. Photographs of


1449 bacterial growth were taken every 24 hours for 2 days or 4 days. For *Salmonella enterica*

1450 isolates, the serovar and the clade A/B status [33,34] are indicated by the colour of the

1451 picture frame. Experiments were carried out as biological triplicates, and a representative

1452 picture is shown for each strain.

1453



1454

1455

Figure 2. Experimental evolution of *S. Typhimurium* in succinate minimal medium.

1456

(A) Growth of *S. Typhimurium* 4/74 displays an extended lag time in M9+Succ medium.

1457

The growth curves of four independent cultures (I-IV) of 4/74 WT in M9+Succ are

1458

presented. Cultures were inoculated with bacteria grown beforehand to stationary phase in

1459

LB. the succinate evolved bacteria were harvested in ESP (50 μ L of culture) and were

1460

grown twice in LB prior to re-inoculation in M9+Succ. (B) The succinate-evolved bacteria

1461

grown fast in M9+Succ in comparison with the WT strain. Growth curves of the succinate

1462

evolved cultures I-IV from (A) in M9+Succ are presented: the 4/74 WT and $\Delta rpoS$

1463

(JH3674) strains were included as controls. (C) Succinate fast growing (Succ⁺) mutants

1464

were detected in liquid M9+Succ 4/74 cultures. Cultures from (A) were spread on LB

1465

plates at the indicated growth phase and growth with succinate was assessed for 15

1466

isolated colonies *per* replicate on M9+Succ agar plates after 48 hours of incubation. The

1467

graph shows the proportion (%) of Succ⁺ clones. ND= not detected. (D) Succ⁺


1468

spontaneous mutants emerge from 4/74 WT bacterial lawns on M9+Succ agar plates. 4/74

1469

WT cultures (~10⁷ CFU) were spread on a M9+Succ agar plates and the picture of a

1470 representative plate was taken after 3 days of incubation at 37°C. For the growth curves
1471 (**A&B**), bacteria were grown at 37°C with aeration in 25 ml of M9+Succ (in 250 ml conical
1472 flasks) with an initial inoculum of $\sim 10^7$ CFU/mL ($OD_{600}=0.01$). Growth phases are indicated
1473 in (**A&C**): Lag phase (Lag); Early exponential phase (EEP); Mid-exponential phase (MEP);
1474 Early stationary phase (ESP).
1475



1476

1477

1478

1479

1480

1481


1482

1483

1484

1485

Figure 3. Growth phenotype of 5 genome-edited *Succ*⁺ mutants and 8 regulatory mutants on solid succinate minimal medium. *S. Typhimurium* strains 4/74 WT, $\Delta rpoS$ (JH3674), Δhfq (JH3584), $\Delta iraP$ (SNW188), $\Delta fliST$ (SNW288), $\Delta cspC$ (SNW292), $\Delta iscR$ (SNW184), $\Delta rbsR$ (SNW294), Δpnp (JH3649), $dctA^{mut1}$ (SNW160), $dctA^{mut2}$ (SNW315), $oxyR^{mut}$ (SNW318), $rrsA^{mut}$ (SNW336), $rrsH^{mut1}$ (SNW314), were spread on M9+Succ agar plates and incubated for 48 hours at 37°C. Experiments were carried out with biological triplicates and a representative picture is shown for each strain.




1486

1487 **Figure 4. Hfq, PNPase and sRNAs inhibit *Salmonella* growth with succinate. (A)** Hfq
 1488 and PNPase inactivation boosts *Salmonella* growth on succinate. **(B)** The co-inactivations
 1489 of the *rpoS* activating sRNAs ArcZ, DsrA and RprA or of the *sdh* repressing sRNAs RyhB-
 1490 1/2, Spf and RybB did not stimulate *Salmonella* growth with succinate. **(C)** Successive
 1491 inactivations of ArcZ, DsrA and RprA in the $\Delta ryhB-1 ryhB-2 rybB spf$ genetic background
 1492 stimulate gradually the growth with succinate. **(D)** The overexpression of *rpoS* abolishes
 1493 totally the Succ⁺ phenotype of the Δpnp mutant, lacking PNPase: growth was assessed for
 1494 strains 4/74 WT and Δpnp , carrying the empty plasmid (vector, pNAW125) or the *prpoS*
 1495 (pNAW95) plasmid, overexpressing *rpoS*. The strains used were all 4/74 derivatives: Δhfq
 1496 (JH3584), Δpnp (JH3649), $\Delta arcZ dsrA rprA$ (JH4385), $\Delta ryhB-1 ryhB-2 rybB spf$ (SNW630),
 1497 $\Delta ryhB-1 ryhB-2 rybB spf arcZ$ (SNW639), $\Delta ryhB-1 ryhB-2 rybB spf arcZ dsrA$ (SNW640)
 1498 and $\Delta ryhB-1 ryhB-2 rybB spf arcZ dsrA rprA$ (SNW641). The medium used is indicated for
 1499 each experiment. Growth curves were carried out with 6 replicates grown in 96-well plates,
 1500 as specified in Methods.

1501

1502



1503

1504

1505

1506

1507

1508

1509

1510

1511

1512

1513

1514


1515

1516

1517

Figure 5. The Succ⁺ *oxyR^{mut}* mutant expresses OxyS constitutively and stimulates *Salmonella* growth with succinate in an Hfq-dependent manner. (A) Schematic representation of the *oxyRS* locus. The Succ⁺ mutation *oxyR^{mut}* has an additional CTA codon encoding for an extra leucine in *oxyR*. (B) OxyS is constitutively expressed in the *oxyR^{mut}* strain. Northern blot detection revealed OxyS expression in strains 4/74 WT, *oxyR^{mut}* (SNW318) and Δ *oxyR* (SNW320) grown in LB and exposed or not to 2 mM H₂O₂ for 30 min (Methods). The detection of the 5S rRNA was used as a loading control. (C) OxyS stimulates *Salmonella* growth with succinate. Growth curves showed the fast growth of the *oxyR^{mut}* strains in comparison with the WT and the *oxyR^{mut} Δ oxyS* (SNW340) strains. Growth is restored in the complemented strain *oxyR^{mut} Δ oxyS *oxyS^{chr+}* (SNW362), carrying a chromosomal *oxyS* copy. (D) The plasmid-borne expression of OxyS stimulates the growth of the WT but not of the Δ *oxyR* mutant. Growth was assessed for strains 4/74 WT and Δ *oxyR* (SNW320), carrying either the empty (vector, pP_L) or the *oxyS* expressing (*oxyS⁺⁺*, pNAW255) plasmids, schematised at the top of the figure. The bent arrows*

1518 represent the constitutive promoter $P_{L\ lacO-1}$ of the Ap^R pP_L plasmid, carrying the *oriColE1*
1519 replicon. (E) Hfq inactivation suppresses the fast growth of the *oxyR^{mut}* mutants. Growth
1520 was assessed for strains 4/74 WT, Δhfq (JH3584), *oxyR^{mut}* (SNW318) and *oxyR^{mut} Δhfq*
1521 (SNW663). The medium used is indicated for each experiment. Growth curves were
1522 performed in 96-well plates, as specified in Methods. The details about the construction of
1523 strains SNW320, SNW340 and SNW362 are depicted in the supplementary Fig S5.
1524




1525
1526

Figure 6. The OxyS sRNA stimulates *Salmonella* growth with succinate by repressing expression of CspC. (A) Overexpression of *cspC* inhibits the growth of the

1527
1528
1529

oxyR^{mut} strain (SNW318), while *hfq* and *rpoS* overexpression have only a mild effect. The *oxyR^{mut}* strain was carrying either the empty (vector, pNAW125), the *prpoS* (pNAW95), the

1530 *phfq* (pNAW45) or the *pcspC* (pNAW92) plasmids, schematised at the top of the figure.
1531 These low-copy Cm^R plasmids are carrying the *ori101** replicon and the genes of interest
1532 are under the control of the strong constitutive promoter $P_{L\ tetO-1}$ (bent arrows). As a
1533 control, the growth of 4/74 WT carrying the empty plasmid (vector) was also assessed. **(B)**
1534 Strategy to test whether the *Salmonella* sRNA OxyS represses the expression of the *yobF*-
1535 *cspC* mRNA at the post-transcriptional level, as previously reported in *E. coli* [65]. The
1536 plasmid-borne translational fusion *yobF::sfGFP* (pNAW258) is depicted and was constructed
1537 as described in Methods and in Corcoran *et al.*, 2012 [121]. This fusion is under the
1538 control of the constitutive promoter $P_{L\ tetO-1}$.SD= Shine-Dalgarno. **(C)** The *yobF::sfGFP*
1539 activity is reduced in the *oxyR^{mut}* strain, that expresses constitutively OxyS: fluorescence
1540 GFP intensities were measured in strains 4/74 WT and *oxyR^{mut}* carrying *yobF::sfGFP*. **(D)**
1541 Prediction of the RNA secondary structure of *Salmonella* OxyS and of *yobF* 5'-UTR, using
1542 Mfold [141]. The putative kissing complex between the two RNA molecules was predicted
1543 with IntaRNA [142] and the corresponding nucleotides are indicated in magenta for *yobF*
1544 5'-UTR or in blue for OxyS. The mutation *oxyS^{GG}* is indicated and the corresponding
1545 nucleotides are framed. **(E)** The plasmid-borne overexpression of OxyS represses the
1546 *yobF::sfGFP* activity and the *oxyS^{GG}* mutation attenuates this repression: fluorescence GFP
1547 intensities were measured in the $\Delta oxyS$ strain (SNW338) carrying *yobF::sfGFP* and the
1548 empty (empty vector, pP_L), the pP_L-*oxyS* (*oxyS^{WT}++*, pNAW255) or the pP_L-*oxyS^{GG}*
1549 (*oxyS^{GG}++*, pNAW259) plasmids. **(F)** The *oxyS^{GG}* mutation reduces the growth of the
1550 *oxyR^{mut}* strain: strains 4/74 WT, *oxyR^{mut}* and the *oxyR^{mut}* mutant carrying the *oxyS^{GG}*
1551 mutation (SNW670) were grown in M9+Succ. **(G)** Effects of *rpoS* overexpression on the
1552 growth of the $\Delta cspC$ mutant: the strains 4/74 WT and $\Delta cspC$ (SNW292), carrying either the
1553 empty plasmid (vector, pNAW125) or the *prpoS* (pNAW95) plasmid were grown in
1554 M9+Succ.
1555 For A, F and G, growth curves were carried out in the indicated medium with 6 replicates
1556 grown in 96-well plates. For C & E, strains were grown to OD₆₀₀ ~ 2 in LB, supplemented
1557 with the appropriate antibiotic(s). GFP fluorescence intensities were measured, as
1558 specified in Methods. The graphs represent the relative fluorescence intensities (%), in
1559 comparison with the indicated reference strain (100% of intensity). The same strains
1560 carrying GFP fusions were grown on LB agar plates and pictures were taken under blue
1561 light exposure. The data are presented as the average of biological triplicates \pm standard
1562 deviation and the statistical significance is indicated, as specified in Methods.
1563



1564

1565

1566

1567

1568


1569

1570

1571

Figure 7. IscR represses the expression of DctA and inhibits *Salmonella* growth upon succinate. (A) Detailed schematic representation of the *dctA* promoter (P_{dctA}) region in *S. Typhimurium* (*S. Tm*) 4/74 and in *E. coli* MG1655. Conserved nucleotides in 4/74 and MG1655 are highlighted in light gray. The promoter -35 and -10 boxes and the transcription start site (TSS, numbering +1) are indicated according to Davies *et al.*, 1999 [73]. The DcuR binding site [143] and the putative CRP binding site [73,74]. A putative IscR binding site is depicted and the mutations identified in the Succ⁺ mutants *dctA^{mut1}* and

1572 *dctA^{mut2}* are indicated in red. In addition, the corresponding region of *E. coli* B strain
1573 REL606 is depicted: in this strain, a G→A SNP (in red) causing *dctA* up-regulation and the
1574 stimulation of succinate utilisation was previously described [81]. SD = Shine-Dalgarno
1575 motif. Promoters (*P*) are represented by bent arrows. The symbol “*” denotes that the
1576 binding sites were not experimentally demonstrated. **(B)** The stimulation of DctA
1577 expression and the *dctA^{mut1}* and *dctA^{mut2}* mutations boost *Salmonella* growth with
1578 succinate. The AHT-inducible strain *tetR-P_{tetA}-dctA* (SNW133) is depicted: the *tetR*
1579 repressor gene, the *P_{tetR}* and the *P_{tetA}* promoters are indicated. The residual FLP
1580 recognition target site sequence is denoted by “*frt*”. In the absence of AHT no growth was
1581 detected for both WT and *tetR-P_{tetA}-dctA* strains, while AHT addition stimulated the growth
1582 of the *tetR-P_{tetA}-dctA* strain. Similarly, the *dctA^{mut1}* (SNW160) and *dctA^{mut2}* (SNW315)
1583 strains displayed a fast growth in M9+Succ. **(C & D)** The SNP mutations *dctA^{mut1}* and
1584 *dctA^{mut2}* and the inactivation of *IscR* stimulate the expression of DctA. The chromosomal
1585 transcriptional/translation *dctA::sfGFP* fusion is depicted: *sfGFP* encodes for the superfolder
1586 GFP fused in frame to DctA C-term. The GFP fluorescence intensity was measured in
1587 strain WT *dctA::sfGFP* (SNW296), *dctA^{mut1} dctA::sfGFP* (SNW310), *dctA^{mut2} dctA::sfGFP*
1588 (SNW316), Δ *iscR* *dctA::sfGFP* (SNW329) and Δ *rpoS* *dctA::sfGFP* (SNW313). **(B)** Both Apo-
1589 and holo- forms of *IscR* repress *Salmonella* growth with succinate. The growth was
1590 assessed for strains 4/74 WT and Δ *iscR* (SNW184) carrying either the empty plasmid
1591 (vector, pXG10-SF), the *piscR* (pNAW96) or the *piscR^{3CA}* (pNAW97) plasmids. The
1592 *piscR^{3CA}* expressed the *IscR^{3CA}* variant that prevents the binding of an iron-sulphur cluster,
1593 maintaining *IscR* in its apo-form (see text for details). Growth curves **(B & E)** were carried
1594 out in the indicated medium with 6 replicates grown in 96-well plates. For **C & D**, strains
1595 carrying the *dctA::sfGFP* fusion were grown in M9+Gly+Succ to OD₆₀₀ 0.5-1 and GFP
1596 fluorescence intensity was measured by fluorescence microscopy **(C)** or by flow cytometry
1597 **(D)**, as specified in Methods. The graph **(D)** represents the relative fluorescence intensities
1598 of each strain (%), in comparison with the WT strain carrying *dctA::sfGFP* (SNW296, 100%
1599 of intensity). The data are presented as the average of biological triplicates \pm standard
1600 deviation and the statistical significance is indicated, as specified in Methods. NS, not
1601 significant.
1602




1603
1604

Figure 8. RbsR and FliST inhibit *Salmonella* growth upon succinate via RpoS. (A)

1605 RbsR inactivation reduces the cellular level of RpoS in exponential and early stationary
1606 phases. Strains 4/74 WT and $\Delta rbsR$ (SNW294) carrying the empty (vector, pXG10-SF) or
1607 the *prbsR* (pNAW93) plasmids were grown in LB (without Cm) to late exponential
1608 ($OD_{600} \sim 1$), early stationary ($OD_{600} \sim 2$) and stationary phase ($OD_{600} \sim 4$). The cellular levels
1609 of RpoS and DnaK (loading control) were assessed by Western blotting (Methods). As
1610 negative control, the $\Delta rpoS$ mutant (JH3674) carrying pXG10-SF was included. The
1611 experiment presented is representative of three independent experiments and two
1612 replicates are presented in Fig S7B. (B) RbsR inactivation reduces red, dry and rough
1613 (RDAR) morphotype, another RpoS-dependent phenotype. The RDAR phenotypic assays
1614 were carried out as specified in Methods with strain 4/74 WT, $\Delta rbsR$ and $\Delta rpoS$ carrying
1615 the indicated plasmids (vector = pXG10-SF). At least three independent experiments were
1616 performed, and representative RDAR colony pictures are presented. The plasmid-borne
1617 *rpoS* overexpression suppresses the Succ⁺ phenotype of the $\Delta rbsR$ (C) and $\Delta fliST$ (D)
1618 mutants. Growth was assessed in the indicated medium in a 96-well plate for strains
1619 $\Delta rbsR$ (SNW294) or $\Delta fliST$ (SNW288) carrying either the empty plasmid (vector,

1620 pNAW125) or the *prpoS* plasmid (pNAW95) and strains 4/74 WT carrying the empty
1621 plasmid.
1622
1623



1624

1625

1626

1627

1628

1629

1630

1631

1632


1633

1634

1635

Figure 9. Mutation of the 16S rRNA aSD motifs and sub-inhibitory concentrations of chloramphenicol stimulate *Salmonella* growth upon succinate. (A) Schematic representation of the *Salmonella rrmA* and *rrmH* ribosomal RNA (rRNA) operons. The 23S (*rrl*), 16S (*rrs*) and 5S (*rrf*) rRNAs and the *ileT*, *ileV*, *alaT* and *alaU* tRNAs are represented, according to the annotation of the corresponding loci of *S. Typhimurium* LT2 (Genbank AE006468.2)[144]. The bent arrows represent the ribosomal promoter. The replacement of the full *rrsA* and *rrsH* loci (promoters included) with an I-SceI-Km cassette (Methods) in strains Δ *rrsA* (SNW335) and Δ *rrsH* (SNW311) is represented by the “ Δ ” symbol. The SNP mutations in the anti-shine-Dalgarno (aSD) motifs of mutant *rrsA*^{mut} (SNW336) and *rrsH*^{mut} (SNW314) are indicated in red. (B) The aSD mutations *rrsA*^{mut} and *rrsH*^{mut} stimulate *Salmonella* growth with succinate, while the full inactivation of the *rrsA* and *rrsH* loci

1636 (strains $\Delta rrsA$ and $\Delta rrsH$) did not affect the growth (**C**). The plasmid borne overexpression
1637 of *rpoS* has moderate effects on the growth of the *rrsA^{mut}* (**D**) and *rrsA^{mut}* (**E**) mutants with
1638 succinate. The 4/74 WT and the *rrs* mutants carried the empty plasmid (Vector, pNAW125)
1639 or the *prpoS* (pNAW95) plasmid. (**F**) Subinhibitory concentration of chloramphenicol (Cm)
1640 stimulate *Salmonella* growth with succinate. All the growth curves were carried out with 6
1641 replicates in 96-well plates with the indicated medium.
1642



1643

1644

1645

1646

1647

1648

1649

1650

1651

1652

1653

1654

1655

1656


1657

1658

Figure 10. A model depicting the modulation of *Salmonella* succinate utilisation by multiple environmental stimuli. (A) RpoS expression stimulation by Hfq, PNPase, sRNAs and RbsR inhibit *Salmonella* succinate utilisation. The sRNAs ArcZ, DsrA and RprA stimulate *rpoS* mRNA transcription elongation [53] and translation [52] in concert with Hfq. RpoS represses the transcription of several genes of the TCA cycle, including the *sdh* operon [24,25], inhibiting succinate catabolism and *Salmonella* growth with this C-source. PNPase presumably represses succinate utilisation indirectly by its role in the stabilization of several Hfq-associated sRNAs [145] and in the translational activation of *rpoS* [54]. The ribose sensor RbsR stimulates the expression of RpoS, presumably at the post-transcriptional level (Fig 8), repressing growth upon succinate. **(B)** The sRNAs RyhB-1, Spf and RyhB repress *sdh* mRNA translation [47,48] in concert with Hfq and attenuate succinate dehydrogenase (SDH) synthesis, inhibiting *Salmonella* growth upon succinate. In addition, PNPase may promote the degradation of the *sdhCD* mRNA [146]. **(C)** Under aerobic conditions, succinate is mainly imported by DctA [44]. DctA interacts with the DcuS protein and acts as a co-sensor of C₄-dicarboxylates [72,147]. In the presences of

1659 succinate, DcuS/DctA activates the response regulator DcuR, that stimulates the
1660 expression of several genes, including *dctA* [143]. *De novo* synthesised DctA accumulates
1661 and increases the uptake of succinate and DctA accumulation may also stimulate the
1662 transcription of succinate utilisation genes in concert with DcuS/R. However, in
1663 *Salmonella*, *dctA* expression is robustly repressed by the both halo- and apo-forms of the
1664 iron-sulphur cluster regulator IscR (Fig 7), which is up-regulated under iron limiting
1665 conditions [133]. Therefore, IscR plays a pivotal role in the succinate utilisation repression
1666 and blocks *Salmonella* growth with this C-source. (D) OxyR is stimulated by oxidative
1667 stress and stimulates the expression of the sRNA OxyS. OxyS stimulates *Salmonella*
1668 succinate utilisation by repressing the small RNA binding protein CspC. CspC represses
1669 succinate utilisation by a still unknown mechanism. (E) Stressors that alter *Salmonella*
1670 translational capacity (*i.e.* 16S rRNAs mutations, antibiotics or environmental stressors)
1671 stimulate succinate utilisation by a still unknown mechanism. Interrogation marks indicate
1672 speculative interactions.
1673


1674 **Supplementary Figures**



1675

1676 **Figure S1. Growth assessment of *Salmonella* mutants with diverse C-sources**
 1677 **involving a chromosomal construct to complement the *rpoS* mutation.** (A) the growth
 1678 of a collection of *S. Typhimurium* 4/74 mutants lacking regulatory proteins was assessed
 1679 on solidified M9+Succ agar and in liquid M9+Succ medium (in microplates), revealing the
 1680 fast growth of mutants $\Delta rpoS$ (JH3674), Δhfq (JH3584) and Δpnp (JH3649). (B&C)
 1681 Chromosomal complementation of the $\Delta rpoS$ mutation: a copy of *rpoS* (including its native
 1682 promoter, bent arrow), linked to the *cat* Cm resistance gene was inserted in the non-
 1683 transcribed pseudogene *STM474_1565* of 4/74 WT (strain 4/74 *rpoS*^{2x}, SNW226) and of
 1684 $\Delta rpoS$ ($\Delta rpoS + rpoS$, JH4160). The *STM474_1565* gene is also known as *STM1553* or
 1685 *SL1344_1483*. RpoS-dependent phenotypes were assessed for each strain: growth was
 1686 tested in M9+Succ (B) and RDAR phenotype was tested on Congo Red agar plates,
 1687 confirming the Succ⁻ RDAR⁺ of the complemented strain $\Delta rpoS + rpoS$. (D) The growth of
 1688 the novel Succ⁺ mutants identified (presented in Fig 3) was tested on solidified M9 minimal
 1689 medium supplemented with 40 mM citrate, malate or fumarate. The growth was assessed

1690 with biological triplicates after the indicated incubation time (37°C) and the growth of each
1691 mutant was compared to 4/74 WT (Succ⁻) and $\Delta rpoS$ (Succ⁺).
1692




1693

1694 **Figure S2. Genetic dissection of the *fliDST* operon reveals that *fliS* and *fliT* can**
1695 **inhibit succinate utilisation. (A)** Schematic representation of the *fliDST* operon. The
1696 transcription start site (+1 TSS) and the two Tn5 transposon insertions causing Succ⁺
1697 phenotype are depicted (Table 1). **(B)** The inactivation of the flagellar chaperones FliS and
1698 FliT stimulates *Salmonella* growth with succinate. The growth of 4/74 WT and of mutants
1699 $\Delta fliD$ (SNW278), $\Delta fliS$ (SNW280), $\Delta fliT$ (SNW282), $\Delta fliDST$ (SNW284), $\Delta fliDS$ (SNW286),
1700 $\Delta fliST$ (SNW288) was assessed on M9+Succ agar plates after 48 hours of incubation at
1701 37°C.

1702

1703

1704



1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715


1716

1717

1718

Figure S3. Genetic complementation of eight *Succ*⁺ regulatory mutations. (A) The plasmids used for the complementation experiments are depicted and were constructed (Methods) using the backbone of pXG10-SF [121], a low-copy plasmid encoding for the *cat* resistance gene and carrying the *ori101** replicon. Each plasmid carries the gene(s) of interest under the control of the strong constitutive promoter $P_{L_{tetO-1}}$ [123], except for *pnp*, that is controlled by its native promoter. For each growth curve (B-I), the plasmid pXG10-SF (“vector”) expressing the *lacZ*¹⁸⁶::*sfgfp* fusion was used as a negative control. The strains 4/74 WT, $\Delta rpoS$ (JH3674), Δhfq (JH3584), Δpnp (JH3649), $\Delta iraP$ (SNW188), $\Delta iscR$ (SNW184), $\Delta rbsR$ (SNW294), $\Delta cspC$ (SNW292) and $\Delta fliST$ (SNW288) carrying the indicated plasmids were grown in M9+Succ, supplemented with 25 μ g/mL Cm. (J) The presence of Cm (25 μ g/mL) in M9+Succ stimulates mildly the growth of 4/74 WT carrying pXG10-SF. The growth curves were carried out with 6 replicates in 96-well plates.

1719



1720

1721

Figure S4. *Salmonella* growth with succinate is not stimulated by iron

1722

supplementation or the inactivation of sRNAs RyhB-1 and RyhB-2. Strains 4/74 and

1723

$\Delta ryhB-1 ryhB-2$ ($\Delta ryhB-1/2$, JH4390) were grown in M9+Succ medium supplemented or


1724

not with iron (FeCl₃) at the indicated concentration. The growth curves were carried out

1725

with 6 replicates in 96-well plates in the indicated medium.

1726




1727

1728 **Figure S5. Detailed schematic representation of the *oxyS-oxyR* intergenic region**
 1729 **and of the $\Delta oxyS$, $\Delta oxyR$ and *oxyR^{chr+}* constructs.** The intergenic region sequence is
 1730 depicted and the -35 and -10 boxes of the *P_{oxyS}* and *P_{oxyR}* promoters are highlighted in
 1731 blue, according to the corresponding locus of *E. coli* K-12 [59]. The $\Delta oxyS$ and $\Delta oxyR$
 1732 mutation are indicated. The transcription start sites (TSS) are indicated, according to the
 1733 SalcomMac transcriptomic database [108,133]. For the complementation of the $\Delta oxyS$
 1734 mutation in strain SNW362 (*oxyS^{chr+}*), the *oxyS* gene, its native promoter and a *Km^R*
 1735 cassette were inserted into the non-transcribed pseudogene *STM474_1565* [117].

1736


1737



1738

1739 **Figure S6. Stimulation of *dctA* expression in the *dctA^{mut1}*, *dctA^{mut2}* and $\Delta iscR$**
 1740 **mutants. (A-N)** Strains carrying the chromosomal transcriptional/translational fusion
 1741 *dctA::sfGFP* were grown in M9+Gly+Succ minimal medium (OD₆₀₀~1) and the GFP


1742 fluorescence intensity was measured with the IntelliCyt iQue® Screener PLUS (Sartorius)
1743 after bacteria fixation with formaldehyde. The 4/74 WT (untagged strain) was used as a
1744 negative control (**A**). Each Succ⁺ mutants carrying *dctA::sfGFP* was compared with the “WT”
1745 strain carrying the same fusion (SNW296, in grey). (**O**) The *dctA::sfGFP* tagged strain Δ *iscR*,
1746 *dctA^{mut1}*, *dctA^{mut2}* and Δ *rpoS* grow fast in M9+Succ in comparison with the *dctA::sfGFP*
1747 tagged WT strain, showing that the fusion of sfGFP to the C-term of DctA does not impede
1748 the DctA-driven uptake of succinate. (**P**) The same strains were grown in M9+Succ
1749 (OD₆₀₀~1) and the *dctA::sfGFP* induction was observed by fluorescence microscopy, as
1750 specified in Methods. The *dctA::sfGFP* tagged Succ⁺ mutants used for these experiments
1751 were: Δ *rpoS* (SNW313), Δ *hfq* (SNW309), Δ *iraP* (SNW423), Δ *fliST* (SNW330), Δ *cspC*
1752 (SNW424), Δ *iscR* (SNW329), Δ *rbsR* (SNW425), Δ *pnp* (SNW437), *dctA^{mut1}* (SNW310),
1753 *dctA^{mut2}* (SNW316), *oxyR^{mut}* (SNW426), *rrsA^{mut}* (SNW374) and *rrsH^{mut}* (SNW331).
1754



1755

1756 **Figure S7. RbsR stimulates *rpoS* expression at the protein level but not at the**
 1757 **transcriptional level. (A)** Western blot detection of RpoS and DnaK (loading control) in
 1758 4/74 WT and mutants $\Delta rpoS$ (JH3674), $\Delta iraP$ (SNW188), $\Delta cspC$ (SNW292), $\Delta fliST$
 1759 (SNW288), $\Delta rbsR$ (SNW294) and $oxyR^{mut}$ (SNW318) grown in LB to OD_{600} 1 and 2.5. (B)
 1760 Two independent replicates of the Western blot analyses presented in Fig 8A confirmed
 1761 the down-regulation of *rpoS* in the $\Delta rbsR$ mutant (see Fig 8A legend). (C) Schematic
 1762 representation of chromosomal P_{rpoS} -*gfp* transcriptional fusion. The *gfp*⁺ gene and its
 1763 Shine-Dalgarno (SD) were inserted downstream of the main promoter of *rpoS* (P_{rpoS} , bent
 1764 arrow), interrupting the *nlpD* gene. The residual FLP recognition target site sequence is
 1765 denoted by "frt". The P_{rpoS} -*gfp* fusion was inserted in 4/74 WT and in $\Delta rbsR$, resulting in
 1766 strain SNW367 and SNW368, respectively. (D) The P_{rpoS} -*gfp* fusion activity was measured
 1767 in the WT and $\Delta rbsR$ genetic background in bacteria grown in LB to late exponential phase

1768 (LEP, OD₆₀₀~1), early stationary phase (ESP, OD₆₀₀~2) and stationary phase (SP,
1769 OD₆₀₀~4). The GFP fluorescence intensity (absolute values) were measured, as specified
1770 in Methods. The data are presented as the average of biological triplicates ± standard
1771 deviation. The difference of fluorescence intensities between the WT and the $\Delta rbsR$ strains
1772 were not significant (NS) in the three conditions tested, as defined in Methods.
1773



1774

1775 **Figure S8. Subinhibitory concentrations of chloramphenicol, but not of tetracycline,**
1776 **stimulate *Salmonella* growth with succinate. (A)** Low concentration of chloramphenicol
1777 (Cm) stimulates the growth of *S. Enteritidis* strain P125109 and of *S. Typhimurium* strain
1778 4/74 with succinate, while tetracycline (Tc) does not affect the growth profile (B).

1779